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Abstract 
This work reports on an investigation into the synthesis, control, and 
stabilisation of iron oxide nanoparticles for biomedical applications using 
magnetic hyperthermia. A new understanding of the factors effecting 
nanoparticle growth in a coprecipitation methodology has been determined. This 
thesis challenges the highly cited Ostwald Ripening as the primary mechanism 
for nanoparticulate growth, and instead argues that in certain conditions, such as  
increasing reaction temperature, a coalescence mechanism could be favoured by 
the system. Whereas in a system with a slower rate of addition of the reducing 
agent, Ostwald ripening is the favoured mechanism.    
     
The iron oxide nanoparticles made in the study were stabilised and 
functionalised for the purpose of stability in physiological environments using 
either carboxylic acid or phosphonate functionalised ligands. It was shown that 
phosphonate ligands form a stronger attachment to the nanoparticle surface and 
promote increased stability in aqueous solutions, however, this affected the 
magnetic properties of the particles and made them less efficient heaters when 
exposed to an alternating magnetic fields. Tiopronin coated iron oxide 
nanoparticles were a far superior heater, being over four times more effective 
than the best commercially available product. Due to its strong response, 
experiments into the antimicrobial properties of tiopronin coated iron oxide 
nanoparticles were undertaken, specifically on Staphylococcus aureus, to our 
knowledge this is the first time magnetic hyperthermia has been used for such an 
application. At concentrations of 50 mg/ml the sample was capable of complete 
bacterial kills following exposure to the in-house magnetic hyperthermia MACH 
system. Aging and oxidation over a period of a month did decrease the 
performance of the particles to kill bacteria using MACH heating, however they 
were still shown to be effective in killing Staphylococcus aureus. 
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Chapter 1  
Introduction and General Theory 
 
The study of nanoscience and technology is a rapidly expanding subject of interest 
for all areas of the scientific community with the chance for many new and exciting 
opportunities.1 Iron oxide is one material that has evoked a surge in research for its 
many possible applications, due primarily to its magnetic properties.2 This thesis 
shows how altering synthesis conditions can affect the size and thus the magnetic 
properties of iron oxide nanoparticles. Following this, further stabilisation, using a 
host of carboxylic acid or phosphonate functionalised ligands, can improve 
biocompatibility of iron oxide nanoparticles, and can be used in magnetic 
hyperthermia which has potential applications in microbial disinfection and cancer 
treatment. 
 
This introductory chapter provides the reader with a background into some of the 
fundamental theories on which the science is based. It will cover magnetism, 
especially focussing on hysteresis and relaxation; and relate this to magnetic heating. 
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The focus compounds for this thesis are nanoparticulate iron oxides as they display 
specific magnetic properties that are desirable for the application of magnetic 
hyperthermia. Other potential biomedical applications for these materials are also 
discussed. The synthetic methodologies that are found in the literature, and the 
problems and solutions for preparing iron oxide nanoparticles for biomedical 
applications are also addressed. 
 
1.1. Nanoscience 
It is arguably Richard Feynman’s famed after dinner lecture in 1959 entitled 
“There’s plenty of room at the bottom” that brought to the consciousness of 
scientists that there was opportunity and benefits from miniaturisation and building 
atom by atom.3 It was not until 1974 that the word nanotechnology was used by 
Taniguchi.4 The eighties produced a surge in interest and discoveries in the field 
which continues today, examples including the discovery of C60,5 development of 
Atomic Force Microscopy and the infamous IBM logo spelt out in single atoms.6, 7  
 
From this the term nanoparticle made its first appearance in the 1980’s.8 Prior to 
this most of these materials were named small particles or colloids. It is the size 
range that defines the materials as nanoparticles and at this length scale the particles 
display unusual and exciting properties that are different from those seen at the 
atomic scale or in the bulk. 
 
Nanoparticles are particles that are in the size range of 1-1000 nm although more 
typically 1-100 nm.9 For a given precursor concentration the smaller the particles 
formed, the more particles there are and this results in a concomitant larger surface 
area per unit volume. It is the combination of small size and large surface area that 
has primarily brought about a surge in research in this field. The increase in surface 
area results in an increase in unsaturated bonds or free coordination sites. This leads 
to increased reactivity in these particles. The melting point is also shown to be 
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reduced. The decrease in size can also affect the electronic properties of the 
material, including size-dependent quantum effects.  
 
1.2. Magnetism 
Magnetic phenomena have been known for many centuries. In fact it was the 
mineral magnetite, which is the principal magnetic material investigated in this 
thesis, that was observed by the ancient Greeks to attract iron to itself.10 
 
A magnetic dipole is best visualised as being a microscopic bar magnet. The 
magnetic dipole moment is analogous to the electric dipole moment and is a vector 
quantity. The magnetic moment direction is from the south to the north of the 
magnet.  
 
1.2.1. Hysteresis 
Hysteresis is an important phenomena exhibited by magnetic materials. This is 
looked at in the form of hysteresis loops which are a measure of the magnetisation 
(M) or applied field (B) against the magnetic field intensity (H). M and B are directly 
proportional as shown in Equation 1-1 (where µo is the permeability of free space, χm 
is the magnetic susceptibility) ; 11 
 
M = µo-1χmB  
Equation 1-1 
 
If the magnetic field is in vacuo then we get H as shown in Equation 1-2; 
 
Bo = µ0H 
Equation 1-2 
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Magnetisation, M, has the units Am-1 as does H. M and B are intrinsically linked by 
the Equation 1-3;12 
 
B = µ0 (H + M) 
Equation 1-3 
 
Hysteresis curves are therefore sometimes referred to as M-H diagrams. If the 
applied field is ramped up from zero, the magnetic moments of the material become 
aligned with the field. This reaches a maximum saturation value whereby all the 
moments are aligned (Mo), therefore Mo can be calculated by the magnitude of the 
moments of all the atoms per unit volume.13 
 
M0 = mn 
Equation 1-4 
 
 
Figure 1-1 An example of a magnetic hysteresis curve/M-H diagram. Coercivity, remanent 
magnetisation and magnetic saturisation are highlighted. 
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Once at the maximum saturation value the applied field is reversed but the values of 
the magnetisation do not match that as before and are instead negative. The value 
on the y axis at which x = 0 is referred to as the remanent magnetisation. 
Conversely the value at x where y = 0 is the coercivity and this is essentially the 
strength of the applied field required to bring the magnetisation of the sample to 
zero after it has been fully saturised in one direction. It is the value of the coercivity 
that defines whether a material is a hard or soft magnet. Hysteresis means ‘to lag’ 
and this is exactly what is seen in a hysteresis loop.13 There is a time lag for the 
moment to realign with the field causing a loop to be formed, as opposed to the 
original path being followed, as shown by the dotted line in Figure 1-1. 
 
The remanent magnetisation and coercivity are also directly dependent on grain size, 
and multi-domain particles tend to be soft with low coercivities and remanence. 
This is because only low fields are required to translate the domain walls. However 
in hard magnets which tend to be single domain particles, you must reverse the 
magnetisation giving rise to high coercivities and remanence, thus giving a bigger 
hysteresis loop.14 
 
1.2.2. Relaxation 
When a magnetic moment is placed into a magnetic field there is a period of time 
for which it relaxes into its equilibrium or steady state condition. This is termed 
magnetic relaxation. There are two different types of relaxation, Néel and Brownian. 
 
Néel relaxation is the time taken for a magnetic vector to ‘flip’ between its energy 
minima due to thermal fluctuations in a zero field. This can be calculated using the 
Néel-Arrhenius equation (Equation 1-5): 
 
τN = τ0 e(KV/kBT) 
Equation 1-5 
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Where τ0 is the attempt time which is around 10-9 - 10-10 s, K is the anisotropy, V is 
the particle volume, kB is the Boltzmann constant and T is temperature.15  
 
Following this in the late 1950’s and early 1960’s W.F. Brown developed Néel's 
theory to take into account Brownian motion, this was named Brownian 
relaxation.16 Essentially instead of flipping directly from one direction to its 
opposing, as in Néel relaxation, it models the relaxation on the vector essentially 
fluctuating around the energy minima and then jumping and fluctuating around the 
other energy minima.17 Brownian relaxation time τB, is defined as (Equation 1-6): 
 
τB = 3Vhyd η  = +D3hyd η 
    kBT          2kBT 
Equation 1-6 
 
Where η is the dynamic viscosity of the solvent, Vhyd and Dhyd are the hydrodynamic 
particle and volume and diameter. This means that the Brownian relaxation time is 
determined by the rotational mobility of the particles.18  
 
1.2.3. The Classifications of Magnetism 
There are many types of magnetism that have been observed. Different 
classifications are defined in this section. It should be noted that the most 
commonly seen are diamagnetism, paramagentism, ferromagnetism, 
antiferromagnetism, ferrimagnetism and superparamagnetism. All materials have a  
diamagnetic component but can also be assigned to other magnetic classifications. 
 
1.2.3.1. Diamagnetism 
As detailed above, diamagnetism is seen in all materials as it arises from paired 
electrons, and is therefore the most observed. Despite this, commonly only 
materials that display only this type of phenomena are termed diamagnetic as the 
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magnitude of the susceptibility is small, and therefore the other types of magnetism 
dominate.  
 
Diamagnetism, unlike all other types of magnetism, is independent of temperature 
and the field applied. It can be considered as negative magnetisation, in that the 
magnetisation and its susceptibility are negative, therefore essentially repulsive. This 
is analogous to Lenz’s Law of 1834 on electromagnetism. Essentially this law states 
that an induced emf will make a current that opposes the current that induced it.19  
 
1.2.3.2. Perfect Diamagnetism 
Perfect diamagnetism (or sometimes referred to as Superdiamagnetism) is observed 
in superconductors and is only seen at low temperatures. When the temperature 
drops below the transition temperature, the magnetic susceptibility is equal to -1.13  
 
The inside of the superconducting (zero electrical resistance) material has an internal 
field of zero when it is below its critical temperature. The Meissner Effect explains 
this phenomena whereby perfect diamagnetism occurs below the superconducting 
critical temperature; the sample surface becomes magnetised to be exactly equal and 
opposing to the applied field, and it is this excluding force which results in the 
material having no internal magnetic field.11 
 
1.2.3.3. Paramagnetism 
Paramagnetism occurs in materials which have unpaired electrons. These electrons 
are randomly orientated and essentially have their own magnetic moment due to 
weak coupling being overcome by thermal energy. The magnetic susceptibility of a 
paramagnetic material is now positive, meaning that they are attracted to magnetic 
fields, not repelled as in diamagnetism. When there is an external magnetic field 
some of the spins align with the field, depending on the moment of the material and 
the external field. Removal of the field enables thermal agitation to dominate which 
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randomises the spins so no net magnetisation is seen. Thus by cooling a 
paramagnetic material the spins are easier to align when an external magnetic field is 
applied. The magnetic susceptibility dependence (often inversely proportional) to 
the temperature is explained by the Langevin Theory.20  
 
 
Figure 1-2 A schematic representing the random spin orientations seen in paramagentism. 
B indicates the direction of the applied field. 
 
1.2.3.4. Pauli Paramagnetism 
Pauli Paramagnetism is the name given to the weak, mostly temperature 
independent type of paramagentism which is found in most metals. Electrons that 
are present in the Fermi surface are paired, implying the material would be 
diamagnetic. However, when an external magnetic field is present there becomes an 
energy gap between the paired electrons in the conduction band. This applied field 
forces the electrons with spins parallel to the field to lower in energy and the 
electrons with opposing spins increase in energy. This then means that the energy 
levels that are spin parallel are preferred and gives rise to a small net 
magnetisation.21 
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1.2.3.5. Ferromagnetism 
The ferromagnet has a long range order, whereby the spins in different 
environments are aligned in parallel below the Curie temperature (Tc). This 
alignment is very strong (albeit not strong enough to form a covalent bond), and 
produces a large net magnetic moment.  
 
Ferromagnetic materials produce hysteresis curves, as described in 1.2.1, as M is not 
proportional to H. There are two types of ferromagnet; hard and soft. The 
hysteresis loops of hard ferromagnets are large and wide and M is still large when 
there is no applied field present, these materials are useful for permanent magnets, 
an example of a hard ferromagnet is cobalt steel. Soft ferromagnets have much 
smaller/narrower hysteresis loops and have a small M when there is no applied field. 
They vary and have a greater dependence on H.22 An example of a soft ferromagnet 
is silicon steel. 
 
 
Figure 1-3 A schematic displaying the ordering of spins in a ferromagnetic material. B 
indicates the direction of the applied field. 
 
However, when Tc is reached and exceeded thermal agitation of the ions becomes 
favoured over the long range order of the magnetic moments. It is the point where a 
material loses its ‘magnetism’ due to the randomised nature of the now unaligned 
moments and thus becomes paramagnetic.  
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1.2.3.6. Antiferromagnetism 
In an antiferromagnet the spins in the different environments are antiparallel when 
below the Néel temperature (TN), they are coupled using a superexchange 
mechanism (not to be confused with a double exchange mechanism which is seen in 
the coupling in Fe3O4 – see 1.3.7.).  These spins are of equal size giving little overall 
net magnetisation, the magnetic susceptibility being comparable to paramagnets (see 
Figure 1-4).23 
 
 
Figure 1-4 A schematic showing the ordering of spins in an antiferromagnet, the overall net 
magnetisation is zero as opposing spins effectively cancel each other. B indicates the 
direction of the applied field. 
 
The superexchange sees the covalent bonding of metal ions with a bridging ligand 
which is 2- (often oxygen). The two electrons in the ligand p-orbital go to the two 
neighbouring metal positive ions and give rise to the two metals having spins that 
are antiparallel.24 With increasing metal-ligand orbital overlap the superexchange 
coupling is stronger, but with increasing metal-ligand angles the lessening in overlap 
makes for a weaker superexchange, and as this reaches 900 the superexchange 
mechanism can also cause ferromagnetic coupling, although this is far less common 
than for antiferromagnetism.11 
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Like in the case of Tc, when TN is reached the thermal agitation disorganises the 
spins and the material becomes paramagnetic.  
 
1.2.3.7. Ferrimagnetism 
Ferrimagnetism has similarities to antiferromagnetism, whereby the metal ions in 
the two different environments are opposing, however the two environments have 
magnetic moments of different magnitudes. This results in a net magnetic moment 
being produced (Figure 1-5). Both ferrimagnetism and antiferromagnetism were 
discovered by  Louis Néel.25  
 
 
Figure 1-5 A schematic showing the spin alignments in a ferrimagnet, opposing spins are 
smaller in magnitude thus leaving an overall net magnetisation. B indicates the direction of 
the applied field. 
 
Again, as seen in both ferro- and antiferro-magnetism once the temperature of a 
material is increased, the thermal energy overpowers the desire for long range order, 
the spins are randomised and the material becomes paramagnetic. This temperature 
is named the ferrimagnetic Néel temperature (TfN). Ferrimagnetism, in the case of 
magnetite, is explained in more detail in 1.3.7. 
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1.2.3.8. Superparamagnetism 
Superparamagnetism is exhibited in single domain particles thus making it a direct 
size effect. In a single domain particle there is a size at which it becomes unstable 
and displays superparamagnetism, conversely at larger particle sizes domain walls 
become prevalent and the system becomes multi-domain. This is also affected by 
shape anisotropy whereby equidimensional grains will have a smaller size where it 
becomes single domain than in anisotropic particles.  
 
 
Figure 1-6 The effect of increasing particle size, by going from a small single domain 
particle to a larger particle results in multi domain materials with domain boundaries. 
 
Superparamagnetic particles have magnetic anisotropy, which means that the 
electron spins align in a preferred orientation which leads to ‘easy’ magnetisation in 
that direction. The cause of this anisotropy can be size, shape or stress.  To 
overcome the anisotropy there needs to be some thermal energy. The temperature 
at which this occurs is called the blocking temperature, TB. The way this energy 
relates to the frequency of flipping is shown in Equation 1-7, 
 
f = fo e(-Eb/kT) 
Equation 1-7 
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Where fo is an attempt frequency, kT is the Boltzmann term. Below TB the (blocked) 
particles have coercivity, remanent and saturation magnetisation, similar to that of 
ferromagnets below the Curie temperature. However above TB they display very 
different hysteresis curves with no coercivity (see Figure 1-7).26 
  
 
Figure 1-7 Below the blocking temperature (TB) a superparamagnet has a broad hysteresis 
curve, similar to what is seen in a ferromagnet. Above the blocking temperature the 
hysteresis curve goes through the origin and has no coercivity. 
 
Unless an applied field is present the superparamagnetic material will show 
paramagnetic characteristics, whereby little or no net magnetisation is seen. 
However when the field is applied the spins align along the line of easy 
magnetisation to provide a net magnetisation (see Figure 1-8). 
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Figure 1-8 With no applied field (B) the spins in a superparamagnet are randomly 
orientated, as seen in a paramagnet. With increasing B, the spins align with the field. 
 
1.2.3.9. Speromagnetism, Asperomagnetism and 
Sperimagnetism 
Spero-, aspero- and speri-magnetism are only seen in amorphous materials. 
Sperimagnetism was the first of this kind that was defined by Coey in 1973, the 
material was initially thought to be antiferromagnetic due to it displaying similar 
magnetic properties, however the spins were randomly arranged but certain 
directions had a greater probability due to strain and were fixed with each other by 
antiferromagnetic coupling between neighbours. In a sperimagnet there are two 
separate environments that either are singly or both have randomly directed spins. 
An example of an sperimagnet is DyCo3 where the cobalt ions display some order.27 
These can often take on a structure analogous to a ferrimagnet.28-30 Speromagnetism 
sees randomly arranged magnetic moments at low temperature but the material still 
having no overall moment. A speromagnet is analogous to an antiferromagnet.27, 30  
Asperomagnets also have randomly aligned spins but they follow an anisotropic 
probability distribution; whereby certain directions are more probable. The net 
magnetic moment is a small amount of the collinear saturation value. An 
asperomagnet is analogous to a ferromagnet. 30-32 
 
1.2.3.10. Helimagnetism 
Helimagnetism is only observed at very low temperatures. The magnetic moment 
spins on corresponding neighbours are angled around the axis at an angle of Ф. 
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These moments over a range then create a helical arrangement as seen in Figure 1-9. 
However, if Ф = 00 or 1800 then the structure is ferromagnetic or antiferromagnetic 
respectively.33 
 
 
Figure 1-9 In a helimagnet, seen at low temperatures, the spins are able to align in a helical 
arrangement. 
 
1.2.3.11. Spin Glass 
Spin glasses below the transition temperature TF are frozen magnetically frustrated 
materials which have long range disorder. Due to this there is more than one 
ground state which the spin glass can exist at. Like in the other cases, above TF the 
thermal energy overrides the magnetic intercommunication.34 
 
1.3. Iron Oxide 
The iron ions present in iron oxides are known to give rise to  many of the magnetic 
properties, as described above. This section looks at iron and the iron oxides and 
explains the structures that give rise to the magnetism. 
 
1.3.1. Iron 
Iron is a highly abundant element on Earth, existing rarely in its elemental state due 
to it being readily oxidised into forms such as oxides, chlorides and sulphates. It has 
a great many uses and humans have made use of these throughout history. It is 
commonly alloyed with other metals to increase its strength, such as in steel. 
Chapter 1                                                          Introduction and General Theory 
 
16 
 
Importantly, iron is also an essential element for life as it is both an electron donor 
and receptor. It is an essential component of haemoglobin and myoglobin.35  Most 
of this iron is bound in cells to proteins. Unbound iron can be toxic upon reaction 
with hydrogen peroxide, this reaction is named the Fenton Reaction or the Haber-
Weiss reaction. This produces hydroxyl free radicals as shown in equations 1-8 and 
1-9. 36 
 
Fe2+ + H2O2  Fe3+ + .OH + OH- 
Equation 1-8 
 
Fe3+ + H2O2  Fe2+ + .OOH +H+ 
Equation 1-9 
 
Iron is a first row transition metal and has the electron configuration of [Ar]4s23d6. 
It can take the oxidation states of -2 up to +6, however the most commonly seen 
are 0, +2 and +3.  
 
Iron occurs in many different forms, for example with carbonyls, halides, sulphides, 
hydroxides and cyanides. In this thesis we are concerned only with the iron oxides. 
The iron can be in its +2 or +3 oxidation state or as a combination of the two. The 
iron d-electrons, in its +2 state, experience an octahedral field and are high spin, 
with one pair of electrons in a low energy orbital, and the others occupying the 
other four orbitals. This is because the crystal field stabilisation energy (CFSE) for 
Fe(II) is greater for a tetrahedral arrangement, thus octahedral is favoured. 
Alternatively, in the +3 oxidation state there is no CFSE and either a tetrahedral or 
octahedral environment can be taken and the electrons are again high spin, resulting 
in five unpaired electrons; one in each orbital (see Figure 1-10).37 The structures and 
properties of the known iron oxides are outlined below. 
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Figure 1-10 Crystal field splitting diagrams for Iron (II) and Iron (III) in iron oxide. In all 
cases the arrangements are high spin. However, due to the crystal field splitting energy 
(CFSE) Fe(III) is able to have both an octahedral and tetrahedral arrangement, whereas 
Fe(II) can only be octahedral. 
 
1.3.2. FeO 
FeO sees iron in its +2 state, in fact it is the only binary oxide form which contains 
only Fe(II). The common name is wüstite, named after its discoverer, the German 
metallurgist Fritz Wüst. It has a cubic structure, the common rock salt structure, 
with a cell dimension of between 0.4302-0.4275 nm and has the space group 
Fm3m.37, 38 Wüstite is actually seen with a defect whereby the true stoichiometry is 
Fe1-xO (0.05<x<0.15), where the Fe(II) is oxidised to Fe(III), and also there are 
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defects whereby these Fe(III) ions also occupy interstitial tetrahedral positiions.39 
FeO displays antiferromagnetism at room temperature and TN = 203-211 K. 
 
 
Figure 1-11 The crystal structure of FeO (wüstite). 
 
1.3.3. α-Fe2O3 
Hematite is the common name for α-Fe2O3 and the iron is +3. It is due to its blood 
red colour that it got its name; the Greek word for blood being haima. It assumes a 
hexagonal (rhombohedral) structure (see Figure 1-12). Hematite has the unit cell 
dimensions of a=0.5034 nm and c=1.3752 nm and the space group is R3c.37  
 
At room temperature, hematite is weakly ferromagnetic and below the Morin 
transition (TM) it is antiferromagnetic. TM is 260 K and the TC is 956 K. Below the 
Morin transition the Fe(III) spins are aligned along the c-axis (the trigonal plane) in 
both directions and therefore antiferromagnetic. Upon reaching and exceeding the 
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Morin transition spin flopping occurs resulting in the alignment moving 900 and 
canting results in the spins no longer being perfectly opposite and thus weak 
ferromagnetism is seen.40  
 
Figure 1-12 The crystal structure of α-Fe2O3 (hematite). 
 
1.3.4. β-Fe2O3 
β-Fe2O3 is body centred cubic, where a=0.9398 nm. The space group is Ia3. TN is 
110-119 K and above 770 K it changes into hematite.41 
 
Figure 1-13 The crystal structure of β-Fe2O3. 
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1.3.5. γ-Fe2O3 
Maghemite (γ-Fe2O3) is the oxidised derivative of magnetite and has a defect inverse 
spinel structure due to the cation vacancy; the Fe2+ in magnetite is replaced with ⅔ 
Fe3+ and ⅓ vacancy. The Fe (III) ions occupy both the octahedral and tetrahedral 
sites and due to them being in two different environments it is also ferrimagnetic. 
The Curie temperature for this material is not known although it is believed to be 
between 820 and 986 K, at 400oC it becomes hematite.42  
 
Maghemite can either have a cubic structure (see Figure 1-14) with the lattice 
parameter a being smaller than that of magnetite or it can have a stretched 
tetragonal structure. The cubic structure space group is P4332 and the unit cell 
dimension a=0.83474 nm. The tetragonal structure has the space group P41212 and 
its unit cell dimensions are a=0.8347 nm and c=2.501 nm.37 
 
 
Figure 1-14 The cubic structure of γ-Fe2O3 (maghemite). 
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1.3.6. ε-Fe2O3 
ε-Fe2O3 has an orthorhombic structure with the space group Pna21 and unit cell 
dimensions of a=0.5095 nm b=0.879 nm and c=0.9437 nm (see Figure 1-15). ε-
Fe2O3 has not been synthesised on its own, instead it is in a mixture with other iron 
oxide phases.37 ε-Fe2O3 is antiferromagnetic and TN is 1026 K. 
 
Figure 1-15 The crystal structure of ε-Fe2O3. 
 
1.3.7. Fe3O4  
Fe3O4 has the mineral name of magnetite, it was the first magnetic material 
discovered. The name of the mineral is relatively new, however it comes from the 
word magnet which got its name from the area in Turkey named Magnesia where 
magnetite and thus the magnet phenomena was first seen.11  
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Figure 1-16 A diagram displaying that above the Verwey transition (120 K) double exchange 
occurs, whereby the electron in Fe2+ is able to hop onto the Fe3+ and back again. 
 
The crystal structure of Fe3O4 is that of a cubic inverse spinel type above the 
Verwey transition temperature (Tv) of approximately 120 K, where there is a change 
in conductivity resulting in magnetite going from an insulator to a metal.43 This 
Verwey transition has led to much disagreement about the exact mechanism 
effecting this change. It is believed that at 120 K a double exchange process begins 
from the increase in thermal energy, whereby electrons on neighbouring Fe2+ and 
Fe3+ that occupy the octahedral holes in the lattice are able to hop between each 
other as they are ferromagnetically coupled.44 The fundamental difference between 
double exchange and superexchange is that the electrons do physically move 
between the metal ions in double exchange. This causes the distribution of the two 
ions to become random, and is the reason why magnetite is extremely conductive. 
Unfortunately this does not conclusively explain the whole picture and now there is 
much work being done on looking at some theories proposed by Mott and Ihle-
Lorenz. Mott’s theory works best for low temperature data and the Ihle-Lorenz 
model works better for higher temperature data, briefly the two theories are:45  
 
• Mott’s Model – The Verwey transition is analogous to the phase change of 
a Wigner Glass to a Wigner Crystal, whereby there is tunnelling and range 
hopping of small polarons. 
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• Ihle-Lorenz’s Model – Superposition of polaron band and hopping 
conductivity. 
 
Another area of contention is the space group of magnetite. It is commonly 
interpreted as being the centrosymmetric Fd3m as originally proposed by Bragg but 
Grimes, and others since, have argued it is the non-centrosymmetric F 4 3m.46, 47  
 
 
Figure 1-17 The crystal structures and space groups of Fe3O4 (magnetite). 
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In the unit cell of magnetite, there are thirty-two oxygen atoms which are cubically 
face centred, and the iron atoms occupy sixteen octahedral sites and eight 
tetrahedral sites, whereby the iron (II) sits at half of the octahedral sites and the iron 
(III) is on the other half and all the tetrahedral positions. This is why it is an inverse 
spinel as normal spinels have all the trivalent cations in the octahedral sites and the 
divalent are in the tetrahedral sites (e.g. MgAl2O4).22  
 
Historically, magnetite was believed to be ferromagnetic. It was not until 1948 when 
Néel published his seminal paper ‘Proprieties Magnetiques Des Ferrites – Ferrimagnetisme 
et Antiferromagnetisme’ that it was correctly determined as ferrimagnetic at room 
temperature.25 The iron (III) atoms exist in two different environments; octahedral 
(sublattice B) and tetrahedral (sublattice A). Their spins are opposing and different 
in magnitude, leaving an overall magnetism of the material (see Figure 1-18).  
 
 
Figure 1-18 Fe(III) atoms in octahedral and tetrahedral environments are opposing and 
effectively negate each other, leaving an overall magnetisation occurring from the Fe(II). 
 
At 850 K thermal agitation of the ions become favoured over the long range order 
of the magnetic moments. The material becomes paramagnetic due to the 
randomised nature of the spins (TfN). 
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1.3.8. Synthesis of Nanosized Magnetite and    
Maghemite 
 
The formation of the two desired iron oxide forms; magnetite or maghemite, may 
be done in similar ways. A key aspect is to use iron in the correct oxidation states 
and at the correct ratio. However, it is also important to note the effect oxidation 
will have on the particles. Magnetite is not thermodynamically stable under 
atmospheric oxygen pressure; this is most prevalent in the case of small particles 
which oxidise far quicker than large aggregates of magnetite which degrade over 
geological time.48 Therefore to form Fe3O4 over γ-Fe2O3 an inert atmosphere must 
be created for the reaction and to increase the shelf life it should also be stored in an 
oxygen deficient environment. The iron oxides can be synthesised from both a top 
down (e.g. Ball milling)49 or a bottom up approach to make them nanosized (1-100 
nm). Here we look in depth at the bottom up synthetic methods. 
 
Interestingly, magnetite is synthesised by some birds and fish to assist in navigation. 
An example of such is the homing pigeon which has these in the free nerve endings 
of its beak essentially acting as a compass.50 Magnetotactic bacteria are also being 
investigated as mass cultivation could be used in the production of stable magnetite 
nanocrystals. They use the magnetic nanoparticles to align themselves with the 
Earths magnetic field, hence the term magnetotactic, and were first discovered by 
Richard Blakemore in 1975.51 The bacteria contain magnetosomes which are 
narrowly size distributed inorganic nanoparticles (iron oxides or iron sulphides) 
which are stabilised by a biocompatible organic membrane (a protein and lipid 
bilayer).52 By harvesting the magnetosomes from the magnetotactic bacteria, these 
surfaces can then be functionalised for more specific requirements. 
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1.3.8.1. Solution Based Synthesis of Iron Oxide 
Nanoparticles 
A key synthesis for iron oxide nanoparticles is a solution based method, particularly 
that of co-precipitation. This involves the mixing of solutions of iron(III) and 
iron(II) in a 2:1 ratio and upon addition of a basic surfactant such as ammonium 
hydroxide, iron oxide nanoparticles precipitate forming a colloidal suspension. This 
method has been used for some time and developed since the early 20th century.53 
In this type of synthesis there are some key stages, namely saturation, nucleation and 
growth. Saturation is an important part of the process. For the particles to 
precipitate out they must reach the critical point at which the solution is at 
saturation. As the reactants precipitate out of the solution as small clusters, these 
clusters then go on to act as seeds for which further particle growth may occur. In 
ambient conditions monodispersity can be achieved. This type of model was first 
proposed by LaMer and Dinegar and the reaction scheme model is shown in Figure 
1-19.54 
 
 
Figure 1-19 A replication of the LaMer and Dinegar diagram for how monodisperse 
particles are formed. I is the prenucleation, II is nucleation and III is the growth stage.54   
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Ostwald ripening, named after Wilhelm Ostwald who first discussed this effect, is 
key to understanding the growth process of the nanoparticles.55 When crystallites 
form in solution a growth period occurs, during this time the larger particles begin 
to pull material from the smaller ones thus increasing the size of the already larger 
particles. The reason for this is a thermodynamic one; to decrease the surface 
energy. It is more favourable to have atoms in the bulk than on the surface. 55, 56 
 
 
Figure 1-20 Ostwald Ripening: to decrease the surface energy growth occurs by larger 
particles pulling materials from smaller ones:57 
 
However as is commonly known by many researchers in this field the formation of 
monodisperse nanoparticles is a rather difficult task, and achieving repeatable results 
is difficult to achieve. This could be because there are so many different paths the 
formation can take thus making it highly chaotic and difficult to control.  
 
1.3.8.2. Hydrothermal Synthesis 
Hydrothermal synthesis has been shown to produce iron oxide nanoparticles that 
have a narrow size distribution. The synthesis harnesses the dehydration and 
hydrolysing power of supercritical water to make metal oxides from their salts.58 
This also is a relatively “green method” that does not require the use of organic 
solvents. By altering the reaction conditions, for example precursor concentration 
and solvent ratios, there is an opportunity to tune and select the average size of the 
nanoparticles.59 The hydrothermal synthesis has also been developed by researchers 
using continuous flow techniques, thus allowing for large batches to be produced 
with relative ease, mostly strong bases are required in the synthesis but Adschiri et 
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al. showed that they were able to make 50 nm magnetite nanoparticles using ferric 
ammonium citrate. 60 
 
1.3.8.3. Pyrolysis Synthesis 
Pyrolysis is a common synthetic method for the formation of iron oxide 
nanoparticles. By using high temperatures it is possible to decompose the precursors 
into the desired product. The potential for it to be scaled up very easily for mass 
production is also an important aspect, and there can also be a constant through-put 
for continual production.61 The two types of pyrolysis used are that of spray, also 
known as aerosol decomposition, and laser.62  
 
In spray pyrolysis the precursor can be delivered as either an aerosol carried via the 
gas63, 64 or using an atomiser.65, 66 The stoichiometry of the precursor solution is also 
the stoichiometry of the final product which is very useful for formation of particles 
from multiple precursors.67 Recently Wang et al have made a comprehensive study 
of parameters to control final particle size in ultrasonic spray pyrolysis. Their results 
concluded that the final particle size increased with gas flow rate and spray volume. 
Conversely by the addition of alcohol or increasing the precursor temperature 
and/or concentration the particle size decreased.68 
  
In laser pyrolysis, with the assistance of a continuous wave carbon dioxide laser, it is 
possible to increase the uniformity of the particles by way of varying the laser 
intensity, the pressure in the reactor, oxidation condition and the precursor 
temperature.69, 70 The particles are also free of impurities.71 
 
1.3.8.4. Reverse Micelle Synthesis 
A micelle uses molecules that have a hydrophilic headgroup and a hydrophobic tail 
to form self-assembled aggregates, an example, and commonly used in micelle and 
reverse micelle formation is the phospholipid. In a water based solution the 
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phospholipid tails point towards the centre of the micelle, with the hydrophilic 
headgroups on the surface, these are oil-in-water micelles. A reverse micelle is a 
water-in-oil micelle. The solution is non polar, this causes a reverse of the micelle, 
whereby the hydrophobic tails are on the surface and the hydrophilic headgroups on 
the inside (see Figure 1-21). 72 
 
 
Figure 1-21 A reverse micelle (water in oil micelle) that encapsulates a nanoparticle within 
the aqueous core, this is protected by the hydrophilic (polar) headgroups and the 
hydrophobic (non polar) tails point out into the organic solvent. 
 
This has led to development of the growth of nanoparticles inside the core of the 
reverse micelle. A solution containing dissolved iron salts added into a non polar 
solution containing the phospholipids, causes the phospholipids to collapse around 
the iron salts thus encapsulating them. By then adding a reducing agent such as 
sodium hydroxide it is possible to grow the nanoparticle from the iron salts. The 
benefit of this method is that there is increased size control and uniformity.73 
Researchers have then shown success in coating these particles with elemental gold 
to give increased stability in water.74 However it is problematic to purify the samples 
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and also to phase transfer the magnetic nanoparticles from the non-polar solvent 
into a polar solvent such as water.  
 
1.3.8.5. Matrix Synthesis 
Another primary method in the synthesis of iron oxide nanoparticles is that of  
formation and growth within a matrix. This method allows increased control of the 
shape and size of the product potentially increasing monodispersity. Another 
positive of this approach is the avoidance of synthesis of ‘non-magnetic’ iron oxides 
which often happens in solution based methods. However there are then issues in 
getting the particles out of the matrix and into a dispersion in solution. This tends 
towards a multi-step method to coat the particles for stabilisation, or complex in situ 
methods are developed. The matrices used for the particles are often glassy and use 
traditional solid-state synthesis methods such as ‘shake and bake’ whereby the 
products are ground in a pestle and mortar to create a fine and even distribution. 
This is then placed into a crucible and placed in an oven at high temperatures for 
many days. The glassy matrix is then dissolved away leaving the desired product. 
Müller et al have shown promising results using a borate glass method.75 
 
1.3.9. Properties of Nanosized Magnetite and 
Maghemite 
 
Nanosized materials have reduced dimensionality and show more extensive 
magnetic properties. This is because in the bulk, outershell electrons are more likely 
to be paired in bonding, but when the size is reduced narrower bandwidths are 
observed resulting in larger density of states at the Fermi energy. This means 
magnetic behaviour is more likely to be seen, as explained in the Stoner criterion. 10 
 
Superparamagnetism is a property seen in nanosized materials. Dunlop studied 
single domain/superparamagnetic/multi-domain boundaries, particularly that of 
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magnetite and he used a combination of experimental and theoretical methods to 
calculate the particle size range for superparamagnetism to occur, this being 29-36 
nm at room temperature.76 The size in which single domain begins is denoted d0 
and the diameter at which superparamagnetism occurs ds. do is found to be around 
57 nm ± 5 nm in magnetite.77 The preferred crystallographic orientation which gives 
easy magnetisation in magnetite is the [111].37 
 
1.4. Biomedical Applications 
The use of iron oxide in medicine is not new. Magnetite, although then known as 
Lodestone, was recorded by Hippocrates to be prescribed to control bleeding and 
haemorrhage and treat arthritis and gout as early as 460 BC. In the 10th Century AD 
Avicenna used the powder of iron oxide for an antidote to the swallowing of 
poisonous rust.78 Iron oxide nanoparticles have use in both in vivo (inside the body) 
and in vitro (outside the body) applications, and these are discussed in more detail in 
the following sections. 
 
Due to the special properties possessed by nanosized iron oxide and their potential 
for biocompatibility there is a growth in research in the biomedical applications of 
this material. For this to be successful the iron oxide nanoparticles require surface 
modification for stabilisation in the body and/or for functionalisation to make 
intelligent particles. 
 
1.4.1. Coatings and Stabilisation 
The Brownian motion of nanoparticles in a ferrofluid mean that they collide with 
each other and sometimes upon collision these will aggregate causing them to lose 
their stability in the colloidal suspension and hence precipitate out of the solution. 
The two forces involved in the aggregation are Van der Waals and magnetic dipole-
dipole interactions.79 There are two key ways that this aggregation may be reduced 
or completely stopped and these are: 
Chapter 1                                                          Introduction and General Theory 
 
32 
 
• Electrostatic Stabilisation: Creation of an electrical double layer around 
the particles. 
• Steric Stabilisation: Grafting of polymers to the particle surface. 
 
It is also known that the solubility (hydration energy vs. lattice energy) of Fe (III) is 
extremely small and Fe (II) is not much greater, this means that the solubility of the 
ions at mid-pH (6-8) is difficult.37  
 
 
Figure 1-22 The iron oxide nanoparticle is charged stabilised in solution, whereby the 
hydroxyl anion is on the surface and is then counterbalanced by the N(CH3)4+ cation. The 
cationic atmosphere then aids repulsion between the particles to prevent Ostwald ripening 
and agglomeration. 
 
To prevent the agglomeration of the iron oxide formed by the  co-precipitation 
method tetramethylammonium hydroxide (TMAOH) is often added. It is thought 
that the hydroxide anion is attached to the surface of the nanoparticle and the 
[N(CH3)4]+ cation remains associated to the particle for charge balance (see Figure 
1-22). This cationic atmosphere ensures repulsion between other particulate 
environments.80 The problem with this is that it creates a pH which is not desirable 
for biological applications. At pH 7 this ionic atmosphere is decreased and causes 
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the particles to coagulate making them no longer nanoparticulate. This is an 
important area of research and much work is now involved in looking at coatings to 
stabilise the iron oxides at neutral pH.73 
 
The coatings used to stabilise the particles for use in biomedical applications must 
also be useful for increasing the circulation lifetime inside the body. This is done by 
increasing resistance to opsonisation, which is the adhesion of plasma proteins and 
glycoproteins. Opsonized particles are then easily identified by Kupffer cells in the 
liver which then remove them from the body. The proteins bind quicker and easier 
to hydrophobic particles. 81 
 
Many coatings have been made using organic molecules such as carboxylates, 
siloxanes, sulphates, phosphonates and phosphates.82, 83 The aim is to find a coating 
that is hydrophilic to encourage a stable colloidal suspension in a biocompatible 
medium such as water or phosphate buffer solution (PBS). In the case of carboxylic 
acids it is believed that the acid reacts with the iron around the surface of the 
nanoparticle and is chemisorbed onto the surface. A variety of carboxylic acid 
coatings have been produced including oleic acid, folic acid and lauric acid.84-86  
 
 
Figure 1-23 A demonstration on how the use of long polymeric chains (such as 
polyethylene glycol) can be used to coat nanoparticles and make them stealth by the 
constantly changing conformation making it difficult for the body to recognise them. 
 
Extremely common coatings for iron oxide nanoparticles are hydrophilic polymers, 
particularly dextran, polyethylene glycol (PEG) and polyethylene oxide (PEO). This 
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invites stability in aqueous media and lends itself to being able to associate further 
molecules to it; for instance drugs.87 These coatings also produce “stealth” 
properties as their conformation is constantly changing making it difficult for the 
body to identify and clear them (see Figure 1-23). 
 
Another common coating for iron oxide nanoparticles are liposomes. Liposomes 
are lipid vesicles which can be formed in mono or multilayers of phospholipids. 
These are formed by the collapse of a lipid film by hydration (thus causing a 
swelling) and agitation (to encourage the breakdown of the film), leaving the 
hydrophilic phosphate head group at the surface and the hydrophobic fatty acid 
chains pointing into the liposome.88 The pore inside the liposome allows it to act as 
a vesicle, this has now led to research into making magnetic liposomes 
(magnetoliposomes) for use in magnetic hyperthermia; by collapsing the film in the 
presence of an iron oxide nanoparticle solution (see Figure 1-24).89  
 
 
Figure 1-24 A magnetoliposome; a bilayer with the non polar tails pointing within the layers 
and the polar headgroups on the outside. The nanoparticle is protected inside the core. 
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Importantly the phospholipid shell is biocompatible and encourages stability in a 
pH range desirable for biomedical applications. The surface of the liposome is also 
functionalised, allowing the attachment of targeting molecules, and can be made to 
work in a stealth mode, for example by using PEG.90 91 Alternatively the liposome 
shell can be made cationic by the addition of an appropriate phospholipid, leading 
to faster and increased adsorption to cancer cells, due to an electrostatic interaction 
with their anionic membranes.92 This area has opened up more avenues to achieving 
the long term aim of treating cancer using the magnetic hyperthermia phenomenon 
and has shown promising results in the literature.93 94 
 
1.4.2. MRI Contrast Agents 
Magnetic Resonance Imaging (MRI) has been developed using the principles of 
nuclear magnetic resonance. It uses the magnetic properties of different elements or 
isotopes to build up a detailed picture of the body. This is most commonly seen 
using the proton which is in water. When a proton is in an applied magnetic field it 
will align with the field, when a transverse radio frequency pulse is applied the 
protons become misaligned and then to get back to the aligned steady state 
relaxation occurs. The three influences on the image creation and the types of 
relaxation are:95, 96 
 
• The longitudinal relaxation time, T1  
• The transverse relaxation time, T2 
• The spin energy, ρ 
 
There are two types of contrast agents used in MRI, they are named T1 and T2 
agents. T1 agents tend to be used for the imaging of the blood and capillaries, they 
are generally stealth coated gadolinium particles. Stealth iron oxide nanoparticles 
(e.g. a polymer such as dextran or PEG) are examples of T2 contrast agents and they 
are used in the imaging of the body for diagnostic purposes, e.g. cancers or organ 
trauma, and distribute themselves in the mononuclear phagocyte system (MPS) 
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which consists of organs such as the liver and spleen.97, 98 The contrast agents are 
used as they improve the image by interacting with, and changing, the protons 
relaxation time.99  
 
The iron oxide nanoparticles have to be delivered in dilute concentrations and 
therefore they need to possess large relaxivity values.100 
 
1.4.3. Magnetic Separation 
Magnetic separation is used to separate out a desired material from a mixed solution 
so that it can be further studied at higher concentrations. Examples that have been 
reported in the literature have included the identification of malaria in blood 
samples101 and the detection of rare tumour cells.102 This is achieved by 
functionalising the surface of a magnetic particle with an entity that has an affinity 
for the desired material. The binding of the magnetic particle with the material 
needed for further investigation allows the material to be filtered out from the 
mixed solution by applying an external magnetic field. There are different 
parameters that will effect the particles attraction to the applied field, namely the:103 
 
• Hydrodynamic drag force 
• Mediums velocity and viscosity 
• Desired materials velocity within the medium 
• Magnetophoretic mobility of the particle, largely determined by the size of 
the magnetic particle. 
 
1.4.4. Drug Delivery 
Drug delivery or magnetic drug targeting (MDT) can be achieved using magnetic 
nanoparticles by attaching the appropriate drug to the nanoparticle. After 
internalisation of the functionalised ferrofluid an external magnetic field can then be 
applied to direct the nanoparticles to the desired site (e.g. the organs). Once at the 
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correct location there is the possibility for the cells to take up the drugs or the entire 
nanoparticle-drug entity. By improving drug delivery to the specific target allows for 
a lower drug concentration to be used, thus decreasing negative side effects.99 
 
The external magnetic force must be greater than the blood flow rate, which in the 
case of arteries is 10 cms-1 and for capillaries is 0.05 cms-1, so that the particles are 
kept in the target location.104 
 
1.4.5. Magnetic Hyperthermia 
By exploitation of the magnetic properties of the nanosized iron oxide it has been 
shown that a phenomenon named hyperthermia can be used in the destruction of 
undesirable cells or bacteria.105, 106 This is an exciting potential therapy as it could 
replace or reduce the need for more destructive therapies such as chemotherapy.107, 
108  
 
When a magnetic particle is placed into an AC magnetic field the magnetic moments 
align in accordance to the field (B) as shown by the hysteresis, Figure 1-1 in 1.2.1, 
due to the coupling of the energy supplied from the field with the magnetism of the 
SPION. The energy received from the AC magnetic field is that which is within the 
boundaries of the hysteresis loop and whilst subjected to this field the material 
resistance causes it to give out thermal energy - inductive heating. Depending on the 
size of the particle this can be because of hysteresis or relaxation, because the 
particles are not in a perfect system they have energy losses, heat, because of friction 
with the surroundings. It is this heat loss which is harnessed for use in biomedical 
applications. 
 
As the particle size of an iron oxide nanoparticle decreases, it becomes 
superparamagnetic and reaches the critical size where hysteresis losses become 
unimportant and instead relaxation losses dominate. These losses from relaxation 
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are greater and provide much greater power than hysteric losses from larger ferro- 
or ferri- magnetic particles.109  
 
Cancer, and the conditions in which magnetic hyperthermia can be used to denature 
cancer cells is discussed in more detail in the following section. 
 
1.4.5.1. The Biology of, and Treatments for Cancer 
The area which is causing great excitement is the long term aim that iron oxide 
nanoparticles could be made cell specific and thus be used to target and denature 
cancer cells. In the UK in 2004, 284,560 people were diagnosed with cancer and this 
has steadily increased over the last six years.110 With worrying figures such as one in 
three people getting cancer, and one in four men and one in five women dying from 
the disease, cancer research is a priority not just on a national, but international 
level.111  
 
 
Figure 1-25 The random and uncontrolled growth of cancer cells and how they are spread. 
 
The Penguin Reference Dictionary of Biology describes cancer as being “cells which 
have escaped normal controls regulating growth and division, producing clones of 
dividing daughter cells which invade adjacent tissues and may interfere with their 
activities”.35  In over 90% of cases the mutated DNA has been caused by external 
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factors, these include; diet, smoking, over exposure to UV rays and viruses. In the 
other cases the mutated DNA would have been inherited, this is often seen in breast 
and colon cancers.112 
 
The two main pathways for the development of cancer by affecting the cell cycle are 
the products of either photo-oncogenes or tumour suppressor genes. Photo-
oncogenes code for proteins which are responsible for cell growth and division, 
however if the photo-oncogene is amplified, has a point mutation, or has movement 
of the DNA, it can become cancer causing by way of overstimulating the cell cycle 
and is then named an oncogene. On the other hand tumour suppressor genes which 
limit cell division can also undergo mutation, resulting in the lack of control of cell 
growth and division. In most cases, cancer is normally induced by multiple 
mutations and often both oncogenes and the lack or inactivity of tumour suppressor 
genes are involved. This also explains why the risk of getting cancer increases with 
age, as there are more mutations building up in the genes.113 
 
Treatments of cancer have taken many different pathways, these are often invasive, 
lengthy and cell indiscriminate, leaving the cancer patient feeling very sick. Often 
combinations of treatments are used. The treatments for cancer include:114 
 
• Surgery – the direct removal of a tumour from the body. 
• Chemotherapy – the use of cytotoxic drugs to kill the malignant cells. 
Unfortunately healthy cells can also be damaged by the chemotherapy drugs 
making the patient feel unwell and cause hair loss. However, healthy cells can 
repair this damage whereas cancer cells cannot so die. 
• Radiotherapy – the use of radiation (usually X-rays) to damage and kill 
cancerous cells. There is also an internal radiotherapy whereby a radioactive 
material is placed on or inside the body or ingested as a drink. 
• Immunotherapy – this uses biological materials to kill and inhibit cancer 
growth. Examples of such include; vaccines, gene therapy, cancer growth 
inhibitors and monoclonal antibodies. 
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• Hormonal Therapy – controlling the production of hormones which is 
particularly useful in the treatment of breast and colon cancer. 
• Transplants – particularly of the bone marrow 
• Photodynamic Therapy – drugs that are activated by a light source which 
are able to kill cells. 
• Radiofrequency Ablation – radiowaves which heat and kill cells. 
 
It is anticipated that magnetic hyperthermia could be delivered as a treatment for 
cancer as when the nanoparticles are harnessed to reach a maximum heating 
temperature of 42-45oC for a few hours it can be used alongside the delivery of 
chemotherapy or irradiation, and has been shown to enhance the other treatments. 
However at 500C or above, for a few minutes, it is possible to kill the cell 
completely, this is called thermoblation.115 However, the nanoparticles are 
indiscriminate meaning that they can also kill healthy cells. This makes the delivery 
of the nanoparticles a key issue, and it can be achieved by direct injection of the 
material into the tumour or by adding targeting moieties to the nanoparticle which 
give adhesion to cancer cells specifically.  
 
An example in the literature of targeting magnetic nanoparticles to a tumour include 
the study by Yanase using magnetic cationic liposomes.116 This work showed that by 
coating the SPIONs in a cationic liposome shell there was 10 times the affinity for 
glioma cells compared to neutral liposome shells. This is because cell walls are 
slightly negatively charged and so the positive charge on the magnetosome 
promotes adhesion and internalisation.117 
 
1.4.6. Iron Nanoparticle Toxicity and Iron Excretion 
Studies have shown that iron oxide nanoparticles tend to gather in the liver and 
spleen. They then overtime get incorporated into haemoglobin. One study using a 
SPION named AMI-25 showed there were no acute or subactute toxicity in rats and 
dogs at well over 150 times the recommended dosage.118 A key issue in the toxicity 
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of iron oxide nanoparticles is that there is, as yet, no standardisation of protocol. 
This means that the toxicity is extremely variable, and changes greatly by size, speed 
of dissolution, dose, method of administration and shell composition. Until there is 
more harmonisation this becomes very difficult to predict without extensive in vitro 
and in vivo trials for each methodology and resultant product.119, 120 
 
There are no physiological mechanisms for iron excretion in the body. Instead the 
iron concentrations deplete from the natural loss of cells for example from the skin, 
menstruation, mucus, urine and bowel losses.121 122 
 
1.5. Thesis Outline 
This thesis reports the work undertaken to synthesise iron oxide superparamagnetic 
nanoparticles (SPIONs) that have biocompatibility for application in magnetic 
hyperthermia to be potentially used in cancer treatment. The iron oxides magnetite 
and maghemite are thought to have superior biocompatibility and this is why these 
materials are researched over others such as nickel or cobalt analogues. All the 
samples were synthesised using a co-precipitation method which saw ferric and 
ferrous salts being reduced by a basic surfactant to form the iron oxide.  
 
Chapter 2 briefly explains how the in house magnetic hyperthermia machine works. 
Chapter 3 investigates how by varying the reaction conditions it is possible to have 
increased control, and tailor the size of the nanoparticles to create solutions with the 
desired sizes for optimum heating from magnetic hyperthermia. The heating is 
induced by an in house built system named MACH. 
 
The iron oxide nanoparticles were found to be unstable at physiological conditions 
and are non-targeting. Therefore functionalisation of the nanoparticles with 
carboxylic acid and bisphosphonate ligands was investigated to enable stability in 
aqueous media, by chemisorption onto the nanoparticle surface (Chapters 4 and 5). 
Heating and magnetic data was collected from all the samples. The ligands selected 
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also had other functional groups on them, so that further anchoring of cell specific 
targeting moieties could be developed. The advanced heating of the tiopronin 
stabilised nanoparticle allowed for further antimicrobial testing and is the first time 
magnetic hyperthermia has been used for such an application (Chapter 4).  
 
This thesis is completed by Chapter 6 which covers conclusions and suggestions for 
further work. 
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Chapter 2  
Magnetic Analytical Techniques 
 
2.1. Introduction 
Magnetic analysis can be undertaken using many different strategies, examples 
include; Mössbauer spectroscopy, superconducting quantum interference devices 
(SQUID), gaussmeters, Hall effect magnetometers, Guoy balances and fluxgate 
magnetometers.123 For the purposes of this investigation SQUID was used to 
measure the magnetism of the iron oxide nanoparticle materials, due to availability 
and as it is commonly used in the literature in the measurements of magnetic 
SPIONs.  
 
The overall goal of this work was to produce magnetic nanoparticles that are 
biomedically appropriate, and produce fast and efficient heating to its surroundings 
through magnetic hyperthermia. This is done through an induction heater. The 
induction heater used in these experiments is novel compared to those used in other 
work, and so this is described in further detail, along with the definition and 
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explanation of the parameters used to measure the speed and efficiency of heating 
from the materials. 
 
2.2. SQUID 
 
 
Figure 2-1 A circuit diagram of a dc SQUID superconducting coil, with two Josephson 
junctions. Adapted from Figure 2 in Jenks et al.124 
 
There are two types of SQUID available; the first invented was the direct current 
(dc), and this was followed by the radio frequency (rf) which was invented by Silver 
and Zimmerman in 1967.125 The SQUID works on the phenomena of the 
Josephson junction, defined by Brian Josephson in 1962, which was shortly derived 
after the microscopic theory for superconductivity was given in the BCS theory 
(Bardeen, Cooper and Schrieffer) which described the fundamental particle the 
Cooper pair (an electron pair with a mass of 2m and charge of 2e).126 A Josephson 
junction is two semiconductors that when separated by a thin insulator can have a 
current flow (the electron pairs) through the tunnelling barrier.125, 127 A dc SQUID 
operates with two Josephson junctions (see Figure 2-1) and a rf SQUID operates 
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with one Josephson junction; thus making the dc more sensitive but the rf more 
economical.128 The current generated is dependent on the magnetic flux, and 
therefore the SQUID can be used in magnetic measurement.12 It is also known to 
be very sensitive.72, 124  
 
The SQUID usually operates at very low temperatures (liquid helium cooled), 
however there are now, so-called, high temperature SQUIDs emerging that can 
operate at temperatures around 77 K using conducting ceramics.128 
 
Zero field cooling (ZFC) and field cooling (FC) curves are obtained from a measure 
of magnetisation against temperature in a SQUID (as seen in 1.2.3.8.). The 
information sought from these curves is about energy barriers that exist in a material 
(1.3.7.).129 
 
The SQUID is also able to measure hysteresis curves by measuring the 
magnetisation against the applied field. By taking these measurements at different 
temperatures (e.g. below and above a materials TB) it is possible to gather further 
information on this material; including the saturation magnetisation per unit mass, 
the coercivity of the material and we can also identify superparamagnetism in this 
way, by looking for hysteresis below TB and no hysteresis above TB. 
 
In this work we are looking for evidence of superparamagnetism and a large Ms 
from the materials synthesised. However, it has been shown that although in 
ferromagnetic materials there is a direct correlation with large induced heating 
values (SAR – explained in 2.3.1.) and large Ms and coercivity values, in 
superparamagnetic materials this is not necessarily the case.130 The ZFC/FC field 
curves looks to identify blocking temperatures or Verwey transitions that may be 
present. 
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2.3. MACH 
Magnetic AC Hyperthermia (MACH) is the name of an in house patented machine, 
thought of and developed by Mr Simon Hattersley, Prof. Quentin Pankhurst, Dr. 
Paul Southern and Mr. Mathew Kallumadil. MACH has been developed in response 
to the lack of adequate induction heaters available on the market that satisfy the 
criteria of: 
• Producing large magnetic fields 
• Being tuneable in frequency 
• Being practical in clinical applications 
 
 
 
Figure 2-2 Front view of the 3 turn solenoid (coil) used by the magnetic AC hyperthermia 
(MACH) system to induce heating from a sample. 
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Figure 2-3 A plan view of the coil used in the magnetic AC hyperthermia (MACH) system 
to induce heating from a sample. The image also shows where the sample tube (a 2 ml 
eppendorf) is placed. 
 
The inventors have been able to produce a variety of coil appendages that allow the 
MACH to deliver the inductive heating in a variety of ways, highlighting the 
versatility of the machine, which is essential if taking this further to clinic and allows 
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for self-tuning. Figures 2-2 and 2-3 show such a coil. The sample is placed in an 
Eppendorf (2 ml volume) inside the coil. Upon application of the frequency a 
temperature probe records the temperature increase of the solution over time. 
 
In this work the magnetic AC hyperthermia (MACH) system was powered by 150 
Volts at ca. 0.8 Amps. This encompasses a 2 cm water-cooled coil with 6 windings 
and provided a field of around 12 kA/m at a frequency of 1.05 MHz. The sample 
was placed in the centre of the coil in an eppendorf tube. Full coil details are 
provided in the table below (Table 2-1). 
 
Outer Tube (mm) 5.0 
Inner Tube (mm) 3.0 
Tube thickness (mm) 1.0 
Insulation thickness (mm) 0.25 
Coil inner (mm) 20 
Pitch (mm) 5.5 
Table 2-1 Table giving the dimensions of the 6 turn solenoid used in these magnetic 
hyperthermia experiments. 
 
The MACH is very much still in development and is currently on its fifth 
generation. What it is patented for is the use of the control circuit, the electronic 
breadboard, which generates high magnetic fields in a LC tank, where L is the 
inductor, the coil, and C is the capacitor. In this work the MACH was operated at a 
fixed frequency of 1 MHz, however this frequency can be tuned over a range of 
frequencies using different LC . 
 
2.3.1. SAR and ILP 
Commonly, Specific Absorption Rate (SAR) is referred to in the literature when 
measuring heating properties of magnetic nanoparticles.131 It is also sometimes 
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called the specific loss power (SLP) or specific heating power (SHP). How SAR is 
measured can be seen in Equation 2-1;  
 
SAR = ∆T  .   C 
  ∆t    mFe 
Equation 2-1 
 
∆T/∆t is the initial heat rise, C is the heat capacity of the fluid per unit mass, and 
mFe is the iron mass in the fluid per unit mass. This gives SAR the units W/g.132 The 
fundamental problem with this parameter is that SAR is extrinsic and varies 
depending on both H (field strength) and f (frequency). Therefore measurements are 
only comparable if made on the same machine that has the same H and f.133  
 
This major limitation for comparability led members of this research group (Prof. 
Quentin Pankhurst, Dr. Paul Southern and Mr Mathew Kallumadil) to formulating a 
new parameter. This is named the Intrinsic Loss Power (ILP). This parameter is not 
completely intrinsic (but certainly closer to being so than SAR) and is only true if 
the following assumptions are made:133 
 
 
• The crystallite size has a polydispersity index greater than 0.1 
• Frequencies of several MHz 
• H is much greater than the saturation field of the nanoparticles 
• Similar environmental thermodynamic losses are experienced  
 
Therefore, following these assumptions, ILP is defined as: 
 
ILP = SAR 
         H2f 
Equation 2-2 
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In this work both SAR and ILP will be given, due to SAR still being greatly used in 
the literature.  
 
2.3.2. Usable Frequencies 
As well as the particle size, shape and cell affinity of the nanoparticles, it is also 
important that the heat induction is optimised by both the strength of the magnetic 
field and the frequency, however due to the biomedical application of magnetic 
hyperthermia, research groups have been looking into finding not just the optimum, 
but the safest frequency (f) and field strength (H) possible. 
 
Atkinson et al. in 1984,134 when magnetic hyperthermia for cancer treatment was 
still in its infancy, investigated the effect that inductive magnetic frequencies would 
have on a patient. Their model looked into thermal seeds which were needle like in 
shape, they found that if the needle was orientated parallel to the field there was a 
greater power output than if it was perpendicular. Investigations have now gone 
down the nanoparticle path, for reasons as explained in Chapter 1, however 
Atkinson et al. did endeavour to establish a usable frequency range that would 
provide maximum power output from the material whilst reducing the induction of 
eddy currents within the body tissue. Their suggestion was for the frequency to be 
less than 200 kHz and the overall Hf value should not exceed 4.85 x 108 Am-1s-1.134, 
135 
 
The first clinically approved induction heater operated at maximums of 100 kHz 
and 18kA/m, Hergt and Dutz have suggested that the optimum frequency would be 
around 500 kHz and a field strength of 10 kA/m.136 It has also been put forward 
that the maximum Hf  value is 6 x 106 OeHz for the human body.130 
 
The Hf value is an important consideration in the design of an inductive heater, as 
detailed above, particularly in a clinical application. The design of a tuneable 
machine which can both find an optimum ILP from a particle, alongside being 
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within the biomedical and economical constraints is being investigated by other 
members of this research group. 
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Chapter 3  
Coprecipitation Synthesis 
 
3.1. Introduction 
As described in Chapter 1, the coprecipitation synthesis of iron oxide nanoparticles 
is a solution based methodology, whereby salts in a solvent can be precipitated out 
by making changes to the pH of the solution. In the case of the formation of 
magnetite these are Fe(II) and Fe(III) salts and the pH adjustment normally made is 
to increase the basicity of the solution. This type of synthesis was first developed by 
Massart in 1987.137 The co-precipitation methodology of iron oxide nanoparticles 
still requires refinement, including the ability to control many aspects, including; 
colloidal monodispersity, nanoparticle size tuning, cohesive particle sizing, 
anisotropy and effects of surfactants or coating.138 In this chapter the development 
of an optimised coprecipitation method to iron oxide nanoparticles is presented. 
Notably the particles made from this study were later shown to be the best ever 
particles to date for magnetic hyperthermia. 
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3.1.1. Particle Growth 
The stages involved in the coprecipitation technique are saturation, nucleation and 
growth. These stages need to be controlled so that the resulting product has 
repeatable and desirable properties, particularly in the case of nanoscience we wish 
for size control. The first work that details the growth process of monodispersed 
particle solutions was produced by LaMer and Dinegar and described in 1.3.8.1.54 
Turkevich, when investigating gold sols, found flaws in the LaMer mechanism. He 
proposed an alternative which saw 3 steps; nucleation, growth and coalescence.139  
 
Liftshitz and Slyozov56 described the kinetics of how precipitation occurs in 
supersaturated solutions, they covered two types of diffusion. The first was the 
growth of a grain which then redissolves back into the now only slightly 
supersaturated solution. The other method was the growth of larger particles from 
smaller ones; they named this coalescence, this was a follow on from that that which 
had been described by Ostwald in the Ostwald ripening process (see 1.3.8.1.). 
Liftshitz and Slyozov’s work was further developed by Wagner and the full kinetic 
theory for the speed of growth of grains is called the LSW theory.55  
 
In 1998, Watzky and Finke proposed a new mechanism, following the inadequacies 
with those such as LaMer’s (the model seems to only hold true for closely related 
systems to that of sulphur sols) and Turkevich’s. Their new mechanism suggests 
that there is slow and continuous nucleation followed by a fast and autocatalytic 
surface growth step.140, 141 
 
Tiemann et al. define coalescence as being the collision of two particles at a correct 
orientation causing unity brought about through Brownian motion. They have also 
accumulated the various forms of coalescence defined by various groups in the 
literature and investigated combinations instead of just one mechanism for the 
formation of growth of ZnS nanoparticles.142 
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3.1.2. Particle Size and the Coprecipitation Method 
Groups have shown that by altering conditions in the coprecipitation method it is 
possible to gain control over the nanoparticles size and edge towards 
monodispersity. These methods have included;  
 
• By varying the concentrations of the iron reactants – increasing the 
concentration makes the resulting nanoparticles larger. 143 
• The pH - a stronger reducing agent gives rise to smaller crystals.104  
• Using surfactants – different surfactant types and concentrations can 
improve the nanoparticle synthesis by overcoming interparticle attractive 
forces such as Van der Waals and magnetic.144-146 
• Ionic strength – Increasing the ionic strength of the medium decreases the 
particle size147 
  
3.1.3. Chapter Motivation 
Despite the vast amounts of literature on nanoparticle formation and growth 
kinetics there has not been a thorough investigation on the way surfactant/reducing 
agent addition and temperature, in the iron salt reduction to iron oxide 
nanoparticles, occurs. As detailed above, it is now believed that not only particle size 
and shape but particle cluster sizes are of importance in the type of hyperthermic 
response to an inductive magnetic field.  
 
This chapter looks to fill such a gap in the literature by investigating these two key 
areas: 
 
• The salt solution temperature upon surfactant/reducing agent addition 
• Surfactant/reducing agent rate of addition to the salt solution 
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Our hypothesis is that by measuring particle size, cluster size and polydispersity of 
the nanoparticles in these two experiments, it is possible to identify trends, and 
therefore allow increased control and selectivity when synthesising SPIONs.  
 
3.2. Methodology 
 
3.2.1. Materials 
All chemicals were purchased from Sigma Aldrich and were used as received with 
no further purification; iron (III) chloride hexahydrate (99%), iron (II) chloride 
tetrahydrate (≥99%) and tetramethylammonium hydroxide (25% in water w/w) 
(TMAOH). All water used was distilled and was 15 MΩ. 
 
3.2.2. Synthesis 
To determine the effect of temperature and rate of addition of the reducing agent 
on the particle size the other parameters needed to be kept consistent. All reactions 
were carried out in air in a sealed vessel to maintain the concentration. Steam was 
produced from the exothermic reaction. A 250 ml conical flask was used and all 
reactions were stirred magnetically with a 1.5 cm magnetic stirring bar. The 
FeCl2.4H2O solution was stored under nitrogen until the reaction was due to begin, 
so as to minimise oxidation. A disposable 10 ml standardised syringe was used for 
the addition of the TMAOH. 
 
3.2.2.1. Synthesis for Observation of Temperature Effect 
In a typical reaction 1.485 g, 5 mmol, of FeCl3.6H2O was dissolved in 5 ml of 
distilled water in a 250 ml conical flask. To this 1.25 ml of a stock solution of 
FeCl2.4H2O (0.498 g, 2.5 mmol) was added. The flask was then sealed with a 
subaseal and magnetically stirred on a hot-plate stirrer. A temperature probe and 
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thermocouple was placed inside the reaction vessel and set to the desired 
temperature. Once at this temperature 10 ml of TMAOH was syringed into the 
reaction in one continuous addition, taking 1 minute in total. This was done by 
hand, not using a syringe drive. This reaction was removed from heat (if being 
heated – see Table 3-1) and stirred for a further 45 minutes at room temperature. 
The magnetic stirring bar was then removed and the solution poured into a sample 
vial. The conical flask was washed with 20 ml of distilled water and collected in the 
sample vial. The temperatures chosen for the reactions were room temperature 
(200C), 500C and 700C. See Table 3-1 for an overview of the synthesis parameter. 
 
For TEM, zeta sizer and hydrodynamic size measurements the solutions were 
diluted down to 1 mg of nanoparticle per millilitre of solvent.  
 
3.2.2.2. Synthesis for Observation of the Effect of the Rate of 
Addition of Reducing Agent  
In a typical reaction 1.485 g, 5 mmol, of FeCl3.6H2O was dissolved in 5 ml of 
distilled water in a 250 ml conical flask. To this 1.25 ml of a stock solution of 
FeCl2.4H2O (0.498 g, 2.5 mmol) was added. The flask was then sealed with a 
subaseal and magnetically stirred on a hot-plate stirrer. A temperature probe and 
thermocouple was placed inside the reaction vessel and set to the desired 
temperature (either room temperature or 70 0C). Once at this temperature 10 ml of 
TMAOH was syringed into the reaction in either: 
• Continuous addition over 1 minute 
• In 1 ml increments, every 1 minute  
• Continuous addition over 5 minutes 
• Continuous addition over 10 minutes 
 
 This reaction was removed from heat (if being heated, Table 3-1) and stirred for a 
further 45 minutes at room temperature. The magnetic sti
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removed and the solution poured into a sample vial. The conical flask was washed 
with 20 ml of distilled water and collected in the sample vial. See Table 3-1 for an 
overview of the synthesis parameters. 
 
For TEM, zeta and hydrodynamic size measurements the solutions were diluted 
down to 1 mg/ml.  
 
Reaction 
Number 
Temperature 
 / 0C 
Reducing Agent Addition 
1 20 Continuous addition over 1 minute 
2 50 Continuous addition over 1 minute 
3 70 Continuous addition over 1 minute 
4 20 Incremental, 1 ml added every 1 minute 
5 20 Continuous addition over 5 minutes 
6 20 Continuous addition over 10 minutes 
7 70 Incremental, 1 ml added every 1 minute 
8 70 Continuous addition over 5 minutes 
9 70 Continuous addition over 10 minutes 
Table 3-1 The reaction temperature and the rate of addition of the reducing agent, 
tetramethylammonium hydroxide, in the formation of iron oxide nanoparticles made in a 
co precipitation method for the samples named 1-9. 
 
3.3. Results 
 
The particle size was observed using TEM measurements and hydrodynamic size 
measurements. These were carried out on a Philips EM208 transmission electron 
microscope at a voltage of 120 kV. The zeta measurements and hydrodynamic size 
measurements were obtained using a Zetasizer Nano ZS 
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Mavern, UK). The software ImageJ was used to measure the particle sizes on the 
TEM images. Measurements were taken in triplicate. 
 
3.3.1. Results of Temperature Effect on Particle Size 
The iron oxide nanoparticle samples 1, 2 and 3 were synthesised at room 
temperature, 500C and 700C respectively. They were made by reducing a 2:1 ratio of 
Fe(III):Fe(II) from the metal salts using an excess of TMAOH. The reducing 
agent/surfactant was added continuously from a 10 ml disposable syringe over a 1 
minute period. The reactions were carried out in air, but in a sealed vessel and 
stirred magnetically. The solutions were diluted to 1 mg of nanoparticles per ml for 
all measurements. 
 
Hydrodynamic Size/ 
nm 
Polydispersity Index Sample Reaction 
Temperature  
/0C 1 2 3 Average 1 2 3 Average 
1 20 63 64 64 64 0.22 0.22 0.20 0.21 
2 50 104 104 104 104 0.21 0.21 0.21 0.21 
3 70 111 111 112 111 0.22 0.22 0.18 0.21 
Table 3-2 The hydrodynamic sizes and polydispersity indexes, in triplicate and mean 
average, for three iron oxide nanoparticle samples formed at different reaction 
temperatures in a coprecipitation method. 
 
The hydrodynamic size measurements and their relative polydispersity were 
measured three times for accuracy. The results for this can be seen in Table 3-2. The 
average hydrodynamic size for 1, 2 and 3 were 64, 104 and 111 nm respectively, 
Figure 3-1 shows this graphically for clarity. This shows that with increasing reaction 
temperature there is an increase in the average hydrodynamic size. The 
polydispersity index of all three samples was an average of 0.21 which indicates all 
three preparations gave low particle size dispersity (also shown in Figure 3-1). The 
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line of best fit for the graph indicates a possible proportional relationship between 
temperature and hydrodynamic particle size. The R2 value is 0.93 and the equation 
for the line is; 
 
y = 0.98x + 48 
Equation 3-1 
 
 
 
Figure 3-1 A graph displaying the mean average hydrodynamic size of iron oxide 
nanoparticles formed at different reaction temperatures in a coprecipitation method. The 
error bars indicate the polydispersity and the trend line indicates a possible proportional 
relationship. 
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Figure 3-2 HRTEM images of iron oxide nanoparticles formed by a coprecipitation 
method at different reaction temperatures. A & B = 200C, C & D = 500C, E & F = 700C. All 
scale bars are 100 nm except for D which is 20 nm. 
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Figure 3-3 HRTEM close up image of the iron oxide nanoparticles synthesised via a 
coprecipitation method at 200C. The full image is shown in Figure 3-2, 1B. 
 
HRTEM images were taken for samples 1, 2 and 3. These can be seen in Figure 3-2. 
For clarity on shape and size a close up image of 1 is shown in Figure 3-3. 
 
The zeta potentials for 1, 2 and 3 all gave charge values at -40. This would indicate 
the particles were all negatively charged. 
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Figure 3-4 Histograms showing the spread of the 60 measurements of particle sizes of iron 
oxide nanoparticles synthesised via a coprecipitation method at 200C (1), 500C (2) and 700C 
(3). 
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Sample Reaction 
Temperature / 0C 
Mean Particle 
Size Diameter / 
nm 
Standard 
Deviation / 
nm 
1 20 6.78 1.55 
2 50 7.49 1.92 
3 70 8.75 2.55 
Table 3-3 Table displaying the mean particle size and standard deviation of iron oxide 
nanoparticles synthesised using a coprecipitation method at various temperatures. 
 
 
Figure 3-5 Graph showing the mean particle size and standard deviation for 60 
measurements taken of iron oxide nanoparticles synthesised via a coprecipitation method 
at varying temperatures. A line of best fit is also shown with the formula and R2 value. 
 
Figure 3-4 displays histograms of the 60 particle measurement results for samples 1, 
2 and 3. The mean average of these results and then the standard deviation was 
calculated and the results are shown in Table 3-3 and Figure 3-5. The results indicate 
that with increasing temperature there is a particle size increase and the standard 
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deviation increases indicating increased polydispersity. Figure 3-5 demonstrates this 
graphically and also shows a line of best fit that has the equation; 
 
y = 0.04x + 6 
Equation 3-2 
  
With an R2 value of 0.93. This indicates that there may be a linear dependence on 
particle size with increasing temperature. 
 
3.3.2. Results for Method of Addition of Reducing 
Agent on Particle Size 
The iron oxide nanoparticle samples 1, 4, 5 and 6 were synthesised at room 
temperature. They were made by reducing a 2:1 ratio of Fe(III):Fe(II) from the 
metal salts using an excess of TMAOH. The reducing agent/surfactant was added in 
four separate ways from a 10 ml disposable syringe continuously over a 1 minute 
period, in incremental doses of 1 ml every 1 minute, continuously over 5 minutes 
and continuously over 10 minutes respectively. The reactions were carried out in air, 
but in a sealed vessel and stirred magnetically. 
 
The iron oxide nanoparticle samples 3, 7, 8 and 9 were synthesised at 700C. They 
were made by reducing a 2:1 ratio of Fe(III):Fe(II) from the metal salts using an 
excess of TMAOH. The reducing agent/surfactant was added in four separate ways 
from a 10 ml disposable syringe continuously over a 1 minute period, in incremental 
doses of 1 ml every 1 minute, continuously over 5 minutes and continuously over 10 
minutes respectively. The reactions were carried out in air in a sealed vessel that was 
stirred magnetically. 
 
All the samples were then diluted in water to a concentration of 1 mg of 
nanoparticle/ml for further measurement. 
 
Chapter 3                                                                    Coprecipitation Synthesis 
 
65 
 
Sample Reaction Conditions 
at 200C 
Hydrodynamic 
Size / nm 
Polydispersity 
Index 
1 Continuously over 1 minute 64.0 0.21 
4 Incremental, 1 ml added 
every 1 minute (total time 
period of 9 minutes elapsed) 
58.1 0.26 
5 Continuously over 5 
minutes 
66.6 0.25 
6 Continuously over 10 
minutes 
77.8 0.31 
Table 3-4 The hydrodynamic sizes and polydispersity indexes of iron oxide nanoparticles 
formed via a coprecipitation method at 200C with varying reducing agent addition rates. 
 
Sample Reaction Conditions 
at 700C 
Hydrodynamic 
Size / nm 
Polydispersity 
Index 
3 Continuously over 1 minute 111.3 0.21 
7 Incremental, 1 ml added 
every 1 minute (total time 
period of 9 minutes elapsed) 
298.3 0.43 
8 Continuously over 5 
minutes 
210.7 0.35 
9 Continuously over 10 
minutes 
266 0.41 
Table 3-5 The hydrodynamic sizes and polydispersity indexes of iron oxide nanoparticles 
formed via a coprecipitation method at 700C with varying reducing agent addition rates. 
 
The hydrodynamic size measurements and zeta potentials were measured for all 
cases and TEM images were gathered for the data collected at 700C. Tables 3-4 and 
3-5 show the hydrodynamic diameters and polydispersity indexes for the 
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measurements taken at room temperature (200C) and 700C respectively. In all cases 
the zeta potentials were negative. 
 
Figure 3-6 shows the hydrodynamic sizes of both sets of data displayed in Tables 3-
4 and 3-5.  
 
 
Figure 3-6 Graph displaying the effect of the rate of addition of a reducing agent at 
temperatures of 200C and 700C on the hydrodynamic size of iron oxide nanoparticles 
synthesised using a coprecipitation method. 
 
The polydispersity indexes (PDI’s) for the 8 different samples also varied dependent 
on the type and rate of addition of the reducing agent. The PDI increased with 
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addition time. Also the incremental addition increased the PDI. This can be seen in 
Figure 3-7. 
 
 
Figure 3-7 Graph displaying the effect of the rate of addition of a reducing agent at 
temperatures of 200C and 700C on the polydispersity index of iron oxide nanoparticles 
synthesised using a coprecipitation method. 
 
A plot of the hydrodynamic diameter versus the rate of addition of reducing agent 
was run to look for an inverse relationship (Figure 3-8). The data alludes to this in 
the case of the 700C but less so for the 200C, this may be due to the first 
measurement anomaly (1).  
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Figure 3-8 Graph displaying tentative evidence for an inversely proportional relationship 
between the rate of addition of the reducing agent versus the hydrodynamic cluster size of 
iron oxide nanoparticles formed via a coprecipitation method at 200C an 700C. The 
polydispersity range is indicated by the error bars. 
 
 
TEM images were collected for the data collected at 700C, to identify any effects 
that the rate and type of surfactant addition may have on the particle sizes. These 
TEM images can be seen in Figure 3-9. Figure 3-10 is a close up image of image A 
from Figure 3-9 so that the morphology of the particles can be viewed with greater 
ease. 
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Figure 3-9 HRTEM images of iron oxide nanoparticles synthesised at 700C via a 
coprecipitation method. The rate of addition of 10 ml of reducing agent was varied by A) 
Added over 1 minute B) Incremental, 1 ml added every 1 minute C) Continuously over 5 
minutes D) Continuously over 10 minutes. All scale bars are 100 nm. 
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Figure 3-10 Close up of image A from Figure 3-9. HRTEM of iron oxide nanoparticles 
synthesised via a coprecipitation method at 700C and by adding 10 ml of the reducing agent 
over a 1 minute period.  
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Figure 3-11 Histograms showing 60 particle size measurements per iron oxide nanoparticle 
sample synthesised via a coprecipitation method at 700C. The rate of addition of 10 ml of 
reducing agent was varied by 3) Added over 1 minute 7) Incremental, 1 ml added every 1 
minute 8) Continuously over 5 minutes 9) Continuously over 10 minutes.  
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Sample Reducing Agent 
Addition 
Mean Particle 
Diameter / nm 
Standard 
Deviation / nm 
3 Over 1 minute 8.8 2.6 
7 Incremental 12.4 3.5 
8 Over 5 minutes 11.0 3.0 
9 Over 10 minutes 11.5 3.4 
Table 3-6 The mean particle sizes and standard deviations of 60 iron oxide nanoparticles 
formed via a coprecipitation method at 700C with varying reducing agent addition rates. 
 
 
 
Figure 3-12 Graph showing the inversely proportional relationship between the average iron 
oxide nanoparticle size and the rate of addition of the reducing agent. The error bars 
indicate the standard deviation and each point was the average of 60 measurements made. 
The synthesis was a coprecipitation method at 700C. 
 
Figure 3-11 shows the 60 particle size measurements for 3, 7, 8 and 9. The mean 
average and standard deviation for these results are presented in Table 3-6. When 
converting 3, 8 and 9 into rates of addition (ml s-1) there is an inverse 
proportionality relationship between particle size and the rate of addition of the 
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reducing agent. 7 was omitted from this treatment due to the incremental pattern of 
addition, this was not a steady flow so the rate can not be determined. 
 
Figure 3-12 shows the average particle size against the rate of addition of the 
reducing agent, and also has error bars showing the standard deviation of the 60 
measurements. The graph demonstrates that the line of best fit has and R2 value of 
0.9936 and the equation is; 
 
y = -17.7x + 12 
Equation 3-3 
 
3.4. Discussion 
 
3.4.1. Discussion of Temperature Effect on Particle 
Size 
The results show that increasing the temperature of the coprecipitation reaction 
increases both the nanoparticle crystal diameter and the hydrodynamic diameter of 
the particle clusters. 
 
The average polydispersity of the clusters were all 0.21, indicating that the increase 
in temperature has no effect on creating a wider size distribution; however, when 
looking at these polydispersities graphically (Figures 3-1 and 3-5) it is obvious that 
the actual polydispersity range does increase with reaction temperature. In the case 
of particle size there did seem to be an increase due to the increase in temperature, 
implying there was greater polydispersity in reactions carried out at higher 
temperatures. 
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There seems tentative evidence that both particle diameter and cluster 
hydrodynamic diameter have a linear relationship with increased temperature 
(Figures 3-1 and 3-5). 
 
A plausible explanation for this is that by increasing the reaction temperature there 
is more energy within the solution, this would increase mobility and cause a greater 
number of collisions between the particles. This thermodynamic explanation calls 
into question the commonly put forward effect of Ostwald ripening as the growth 
mechanism. Instead we postulate a different model for the growth mechanism of 
these particles and clusters.  
 
As discussed in 3.1.1., there is an alternative model - coalescence. The data suggests 
that the rise in thermal energy increases Brownian motion and thus collisions. By 
more collisions occurring between the particles, there is a greater probability that 
they will be correctly orientated to join together. This in its very essence is 
coalescence, and in light of the evidence provided this seems the most probable 
mechanism for growth within the coprecipitation of ferrous and ferric ions. It does 
not, however, provide details on the nucleation occurring and further investigation 
would need to be carried out to provide a full model.  
 
This coalescence model in a coprecipitation method seems to mimic the growing 
evidence from Penn and Banfield, that iron oxide particles grow by coalescence in 
orientated attachments in hydrothermal conditions in biomineralisation.148, 149 
 
3.4.2. Discussion on the Method of Addition of 
Reducing Agent on Particle Size 
In the case of hydrodynamic cluster sizes, two sets of data were sought. Both looked 
at how the rate and type of addition would change the size but were carried out at 
two different reaction temperatures; 200C and 700C. For now, the three methods of 
constant addition of the reactant (over 1 minute, 5 minutes and 10 minutes) will be 
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discussed as for these the rate of addition is known. The incremental form of 
addition will be discussed separately. 
 
3.4.2.1. Continuous Addition 
Firstly, in the case of nanoparticle size when the reducing agent is added quickly the 
average diameter decreases, as does the polydispersity. Again, there is tentative 
evidence that there is an indirectly proportional relationship between particle size 
and the rate of addition of the reducing agent (a reactant) as shown in Figure 3-12. 
 
In the case of the hydrodynamic cluster size and for both sets of data there was an 
increase in size when the rate of addition of the reactant was slowed. Following the 
actual particle size, there was again an increase in polydispersity with the larger 
hydrodynamic diameter, thus with the decrease in addition rate. This seems to 
follow an inverse linear relationship between the cluster size and rate of addition, 
although it could be argued that the data sets at 200C are particularly weak, however, 
it does seem evident that the measurements taken at 200C over a 1 minute addition 
seem somewhat of an anomaly and should therefore maybe be discounted (Figure 3-
8). 
 
As seen in the temperature effect results, hydrodynamic cluster size and 
nanoparticle size seem to follow a similar pattern. Both are larger and less 
monodisperse when the rate of addition of the reducing agent is slowed. In this case 
it seems that a thermodynamic explanation is weak and instead a kinetic theory 
seems more likely. By decreasing the rate of addition of the reactant there is a longer 
time for nucleation and growth. This increase in time means that there is no longer a 
short sharp burst of nucleation followed by a growth phase, but constant nucleation 
and growth occurs simultaneously. After nucleation, the smaller particles then get 
engulfed by the larger particles in solution to reduce the surface energy, thus 
following an Ostwald ripening growth mechanism. This would also go somewhat to 
explain the increase in polydispersity; the longer between points of nucleation the 
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longer the time there is for growth, therefore the particles formed at the start of the 
addition would have a longer growth period than those formed at the end of the 
addition. 
 
3.4.2.2. Incremental Addition 
The incremental addition shows surprising results. For the 700C data set the 
hydrodynamic size, particle size and both polydispersity measurements are greater 
than those measured for the continuous addition over 10 minutes. However in the 
200C data set the hydrodynamic size was the smallest of all the measurements and 
the polydispersity was between 5 and 10 minute continuous additions. Even 
forgoing the anomaly that is the continuous addition over 1 minute for 200C the 
hydrodynamic size was less than that of the 5 minute continuous addition.  
 
The incremental addition was carried out by the addition of 1 ml at every 1 minute 
interval, accumulating in a total elapsed time period of 9 minutes (540 s). In both 
data sets the measurements do not fall, as expected, between the 5 and 10 minute 
continuous addition. Infact, the vast differences implies that incremental addition is 
a far less predictable method of adding a reactant to a solution and renders the 
experimentalist helpless in the control of the resultant particle and cluster sizes and 
should therefore be avoided. 
 
Some possible explanations for the results seen are: 
 
• In the case of the 700C data set – Every 1 minute there is a rapid and brief 
period of nucleation, which is then followed by a long growth period before 
the next point of nucleation. In this growth period there are more 
opportunities for bigger particles to form by both coalescence and Ostwald 
ripening. This also gives increased breadth in the size distribution due to the 
time delays between the next point of nucleation and so the gap between the 
first formed and the last formed particles is wider; this follows what has just 
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been described in 3.4.2.1 but is more pronounced because the times of 
nucleation are wider spread and are of greater intensity when they occur. 
 
• In the case of the 200C data set – This result is harder to explain. 
However, this may be possibly due to thermodynamics. When there are the 
short sharp bursts of nucleation there is less thermal energy driving 
Brownian motion, less coalescence occurs, but this is the same for the 
continuous method of addition too. However, a larger concentration of small 
nuclei (more nucleation) in a burst may well limit Ostwald ripening 
compared to a small concentration of small nuclei (less nucleation) occurring 
with greater frequency. This would need much more investigation to be 
conclusive. 
 
3.5. Conclusion - A New Mechanism? 
This investigation hopes to have proved the need to reconsider the long standing 
view in much of the scientific community that nanoparticle growth occurs purely by 
Ostwald ripening.73, 150 Instead, a combined mechanism is more appropriate, which 
models how different reaction conditions may then lead to a preferred growth 
pathway. In the control and desired reproducibility of nanoparticle synthesis the 
thorough understanding of these factors and influences are key, especially if, as in 
the case of SPIONs for magnetic hyperthermia, the eventual aim is for scale-up and 
biocompatibility. Here follows a summary of what has been concluded from these 
results and what needs further investigation. 
 
3.5.1. What we have so far 
The results from this chapter show that: 
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• Changes in particle size and polydispersity are mirrored by hydrodynamic 
size and polydispersity, thus cluster size and particle size are intrinsically 
linked, which is to be expected as bigger particles would form bigger clusters. 
• Temperature of the reaction is proportional to particle size/cluster size and 
polydispersity. 
• This can be explained by thermodynamics whereby increased thermal energy 
gives rise to more particle collisions and the probability of these collisions 
being correctly aligned for agglomeration increases. 
• This implies that with increasing temperature a coalescence mechanism is 
favoured over an Ostwald ripening mechanism for particle growth. 
• This coalescence growth method, as beginning to be believed is the growth 
mechanism in hydrothermal syntheses, looks to be true in a coprecipitation 
synthesis. 
• The rate of addition of the reducing agent is indirectly proportional to 
particle/cluster size and polydispersity. 
• This has a kinetics explanation whereby nucleation and growth are occurring 
simultaneously. The increases in time between points of nucleation allow 
longer growth periods and a greater difference in particle sizes. Therefore an 
Ostwald ripening mechanism is preferred with a decrease in the rate of 
addition of the reducing agent. 
• Adding the reducing agent in a non-continuous form should not be preferred 
as the mechanisms at work are more complicated and the resultant product 
has less predictability. 
 
3.5.2. What is missing 
These results tell us information on temperature and reactant addition rate effects, 
however to build a full and conclusive model on the formation and growth of iron 
oxide nanoparticles in a coprecipitation method, these further additional factors 
would need incorporation; 
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• Reactant concentrations 
• Strength of the reducing agent 
• Surfactant contributions, although in this example the reducing agent is also 
the surfactant 
• Turbulence (mixing) contributions 
 
With this information, and by building a full model that takes into account the 
occurrence of preferential growth mechanisms in different conditions, an automated 
coprecipitation process may be possible that provides the experimentalist with the 
opportunity for size tunability and monodispersity of nanoparticles and nanoparticle 
clusters. 
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Chapter 4  
Synthesis of  Iron Oxide 
Nanoparticles in the Presence of  
Carboxylic Acid Functionalised 
Ligands 
 
4.1. Introduction 
The stabilisation of nanoparticulate iron oxide, as discussed in Chapter 1, is vital for 
biomedical applications, as iron is not stable at physiological pH and will 
agglomerate rendering it useless for cell targeting. Many groups of molecules have 
been shown to interact with the iron oxide nanoparticle surface to give this 
stabilisation. Such examples of this are siloxanes,151-153 phosphonates,154-156 
phosphates157 and long chain hydrophilic polymers such as polyethylene glycol 
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(PEG),158-161 polyethylene oxide (PEO),162 proteins,163, 164 albumin165 and dextran,105 
with the oxygen providing the surface interaction with the iron.166  
 
Another functional group that has been used is the carboxylic acids,167, 168 most 
prominently oleic,86 lauric,169 myristic170 and folic acids.85 Oleic acid, myristic acid 
and lauric acid are long chain fatty acids which are not soluble in water, thus to gain 
water solubility these groups can be substituted with more appropriate molecules or 
have further functionalisation creating a multi-step process, so that a transfer from 
organic solvents to water can be made. Folic acid has been used, as not only is it a 
stabilising agent but it also has some targeting properties useful for the anticancer 
application of magnetic hyperthermia, due to the folate receptors which are 
expressed by areas of new and rapid cell growth, such as that seen in cancers.171  
 
4.1.1. Bacterial Infections 
Hospital acquired infections (HAI’s) are regularly reported in the news and a major 
concern for the government, sparking a huge initiative in trying to irradicate these 
within public buildings which administer health care. This is due to the potentially 
life threatening consequences of infection to a person with an already compromised 
immune system.172  
 
One of the most commonly reported is the various drug resistant Staphylococcus aureus 
group, for example MRSA (methicillin resistant Staphylococcus aureus). These types of 
bacteria are commonly found, and many people are carriers of these bacteria 
without experiencing any sickness. The bacteria becomes significant when a person 
becomes ill and their immune system weakens, resulting in less ability to fight 
infection.  
 
It is therefore of high importance to irradicate these types of harmful bacteria, 
particuarly in places where there are sick people. This has seen advancement in a 
variety of areas including antimicrobial surfaces and coatings, antimicrobial cleaning 
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products and an increased need in finding indiscriminant treatments to replace 
antibiotics to which, overtime, bacteria can build up resistance.173-177  
4.2. Chapter Motivation 
The literature has a wealth of evidence showing that carboxylic acids can be used to 
stabilise iron oxide nanoparticles, preventing agglomeration and promoting 
biocompatibility. However, as described above, these are all long chain molecules, 
C≥12 or a similary sized molecule such as folic acid. There has been little 
investigation into the smaller molecules that contain a carboxylic acid. These 
molecules tend to be hydrophilic due to their polarity and ability to hydrogen bond, 
which is beneficial in both the synthesis of the nanoparticles and for use in forming 
a biocompatible ferrofluid. 
 
Due to the proven reactivity of a carboxyl group with an iron oxide nanoparticle 
other short chain carboxylic acid functionalised ligands were chosen for further 
investigation. Alongside the –COOH group, for attachment chemistry for antibody 
fragments further functional organic groups were needed. This chapter reports the 
findings of the addition of four shorter chained carboxylic acid functionalised 
ligands in a one pot synthesis for the formation of iron oxide nanoparticles. The 
ligands chosen, and the reasons for this, are detailed below in 4.2.1. 
 
This work also shows how magnetic hyperthermia can be used to kill harmful 
bacteria such as Staphylococcus aureus and could be used in treatment for diseases such 
as septacemia. Thermotherapy kills the bacteria and is indiscriminate, meaning that 
the bacteria will not be able to acquire any resistance to hyperthermia treatments. 
The antibacterial study in this chapter is, to our knowledge, the first ever report of 
using magnetic hyperthermia to kill bacteria. 
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4.2.1. Ligand Selection 
Due to the requirements of the project to use magnetic hyperthermia in biomedical 
applications the carboxylic acid functionalised ligands had to satisfy certain criteria. 
These criteria were: 
• They were water soluble so that there would be no need for a phase transfer 
• Had at least one carboxylic acid group for nanoparticle conjugation 
• They had at least one other functional group (carboxylic acids were 
acceptable) for antibody fragment attachment 
• Preferably they were small molecules so that the shell would not dominate 
the core 
• Preferably they had already proven biocompatibility 
 
The ligands selected were aminooxoacetic acid (oxamic acid), butanedioic acid 
(succinic acid), N-(2-Mercaptopropionyl)glycine (tiopronin) and 
ethylenediaminetetraacetic acid (EDTA). See Figure 4-1. 
 
Tiopronin is a pharmaceutical drug which goes under the trade name of Thiola. It is 
used in the treatment of the hereditry disease called cystinuria.178 Cystinuria causes 
kidney stones due to poor cystine reabsorption.179 
 
 
Figure 4-1 The 4 carboxylic functionalised ligands selected to coat iron oxide nanoparticles 
in a coprecipitation method. 
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EDTA is a well known strong chelating agent.35 It chelates strongly to Fe3+. EDTA 
is used biomedically in chelation therapy180, 181 and to enlargen root canals in dental 
surgery.182 
 
4.3. Synthesis 
The methodology was adapted from a hydrothermal synthesis by Daou et al but 
using different conditions and with the addition of ligands.183 The initial part of their 
synthesis was a coprecipitation method which was followed by hydrothermal 
treatment. 10 ml of 1M FeCl3.6H2O was mixed with 2.5 ml of FeCl2.4H2O at 700C 
under argon, followed by the addition of 21 ml of 25% TMAOH. Stirring continued 
for 20 minutes and the contents then placed in an autoclave for the hydrothermal 
treatment. In this work, only the coprecipitation part is done. Furthermore a new 
procedure was worked out for isolating the particles. 
  
4.3.1. Materials 
All chemicals were purchased from Sigma Aldrich and were used as received with 
no further purification; iron (III) chloride hexahydrate (99%), iron (II) chloride 
tetrahydrate (≥99%), tetramethylammonium hydroxide (25% in water w/w) 
(TMAOH), N-(2-Mercaptopropionyl)glycine (tiopronin) (≥98%), aminooxoacetic 
acid (oxamic Acid) (≥98%), butanedioic acid (succinic Acid) (99+%) and 
ethylenediaminetetraacetic acid anhydrous (EDTA) (≥99%). Resovist was received 
from Bayer Schering and Nanomag D100 was kindly donated by Micromod. All 
water used was distilled.   
 
4.3.2. Tiopronin, Succinic Acid and Oxamic Acid 
10 mmol of FeCl3.6H2O in degassed water was placed into a round bottomed flask 
under constant nitrogen flow. To this was added 5 mmol of FeCl2.4H2O in degassed 
water and 5 mmol of either tiopronin, oxamic acid or succinic acid. Due to the 
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magnetic nature of the desired product the reactants were stirred mechanically using 
an overhead stirrer. The flask was heated in a silicone oil bath to 700C. Once at 
temperature, 21 ml of TMAOH (25% in water w/w) was added dropwise to the 
vigorously stirred solution. A black precipitate formed. After addition of the 
TMAOH the flask was immediately removed from the heat source under constant 
stirring. 
 
Once at room temperature the solution was made up to 50 ml with distilled water 
and then transferred to a wet 20 cm strip of dialysis tubing (cellulose membrane, 
M.W. 12,400, average flat width 79 mm). This was secured and fastened at both 
ends and a magnetic stirrer attached. The membrane was placed into a 5 L beaker 
with approximately 4.5 L of 15 MΩ distilled water and stirred by placing on a 
magnetic stirrer plate. The water was recharged daily for 4 days. Upon completion 
of the dialysis, the membrane was removed and its contents placed in a beaker 
whereby the precipitate was removed from the majority of the solvent using a 
strong magnet. The product was placed in a -800C freezer overnight, frozen and put 
under a high vacuum to remove the remaining solvent. This freeze drying process 
took between 2-3 days and left a dry, fine black powder which still displayed 
magnetism characteristics when in a magnetic field. 
 
Generally, approximately 1 g of powder was recovered. 0.5 g of this was suspended 
in 10 ml of deionized water with the aid of sonication in an ultrasonic bath. The 
resultant pH of the three different solutions from the resuspended nanoparticles 
was 6.96, 3.95 and 6.65 for the tiopronin, oxamic acid and succinic acid stabilised 
iron oxide respectively (50 mg/ml and room temperature).  
 
4.3.3. EDTA 
In the case of Ethylenediaminetetraacetic acid (EDTA), the in situ methodology 
needed to be adapted. The strongly chelating chemistry of the EDTA with iron 
meant that an intractable mixture was formed and the iron oxide was no longer free 
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to form nanoparticles. The method was changed so that the EDTA was added post 
nanoparticle formation. 
 
10 mmol of FeCl3.6H2O in degassed water was placed into a round bottomed flask 
under constant nitrogen flow. To this was added 5 mmol of FeCl2.4H2O in degassed 
water. Due to the magnetic nature of the desired product the reactants were stirred 
mechanically using an overhead stirrer. The flask was heated in a silicone oil bath to 
700C. Once at temperature 21 ml of TMAOH (25% in water w/w) was added 
dropwise to the vigorously stirred solution. A black precipitate formed. After 
addition of the TMAOH the flask was immediately removed from the heat source  
under constant stirring. Once at room temperature an aqueous solution containing 5 
mmol of EDTA was added and the solution stirred overnight. This was then made 
up to 50 ml with distilled water and then transferred to a wet 20 cm strip of dialysis 
tubing (cellulose membrane, M.W. 12,400, average flat width 79 mm). This was 
secured and fastened at both ends and a magnetic stirrer attached. The membrane 
was placed into a 5 L beaker with approximately 4.5 L of 15 MΩ distilled water and 
stirred by placing on a magnetic stirrer plate. The water was recharged daily for 4 
days. Upon completion of dialysis, the membrane was removed and its contents 
placed in a beaker whereby the precipitate was removed from the majority of the 
solvent using a strong magnet. The product was placed in a -800C freezer overnight, 
frozen and put under a high vacuum to remove the remaining solvent. This freeze 
drying process took between 2-3 days and left a dry, fine black powder which still 
displayed magnetism characteristics when in a magnetic field. This separation 
technique, although time consuming, is more intensive and effective. Drying the 
particles was initially attempted but this left the particles with excess free reactants, 
which not only affected the mass of the powder, and thus makes concentration 
calculations inaccurate, but also meant that the particles were still at high pH values 
when resuspended. 
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The powder could be resuspended in water with the assistance of sonication in an 
ultrasonic water bath for approximately 30 minutes. The pH of the resultant 
solution at a concentration of 50 mg/ml and at room temperature was 5.38. 
 
4.4. Antimicrobial Testing of Tiopronin 
Stabilised Iron Oxide 
4.4.1. Hyperthermia System 
The magnetic AC hyperthermia (MACH) system was powered by 150 Volts at ca. 
0.8 Amps. This system has been built in-house and encompasses a 2 cm water-
cooled coil with 6 windings and provided a field of around 12 kA/m at a frequency 
of 1.05 MHz. The sample was placed in the centre of the coil. See Chapter 2 for a 
picture of the apparatus set up, the image shows a 3 turn solenoid, however as 
described a 6 turn solenoid of 2 cm diameter was used. 
. 
4.4.2. Bacterial Stains 
The organism used in this investigation was Staphylococcus aureus NCTC 6571.  It was 
maintained as a plate culture and subcultured weekly from freezer stocks on 
Nutrient Agar (Oxoid Ltd, Basingstoke, UK).  For experimental purposes, a single 
colony was inoculated into Nutrient Broth No. 2 (Oxoid) and grown aerobically for 
16 h at 37ºC with shaking.  Cells were harvested by centrifugation and resuspended 
in sterile phosphate buffered saline (PBS) to an OD600nm of 0.05.  In some 
experiments, the adjusted bacterial suspensions were further diluted 1 in 10 and 1 in 
100 in PBS. 
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4.4.3. Magnetic Nanoparticles 
The magnetic nanoparticles used were codified as SPIONTiopronin (iron oxide formed 
in the presence of tiopronin) and SPIONSuccinic (iron oxide formed in the presence 
of succinic acid). Dilutions were made in PBS to obtain the desired concentration. 
SPIONOxamic (iron oxide formed in the presence of oxamic acid) was not used due 
to the low pH that formed on dissolution. 
 
4.4.4. Bacterial Magnetic Hyperthermia 
Aliquots (200 µL) of a suspension of S. aureus NCTC 6571 in sterile PBS, were 
placed into an Eppendorf tube.  To the same tube, 200 µL of magnetic 
nanoparticles were added.  Samples were vortexed and then exposed to the 
hyperthermia heater for the desired amount of time.  The air flow machine was set 
to ~37˚C to maintain a constant temperature.  The temperature of each tube was 
recorded using a Luxtron Fibre Optic Temperature measurement system 
(LumaSense™ Technologies, CA, USA).  Control tubes contained PBS in place of 
magnetic nanoparticles and were exposed to the same conditions.  Control tubes 
containing either PBS or magnetic nanoparticles and the bacterial suspension, were 
not exposed to the hyperthermia heater.  Following exposure to the machine, 25 µL 
aliquots of the test and control samples were taken and added to 225 µL PBS.  Serial 
dilutions were made, and 20 µL aliquots (in duplicate) from each dilution were 
plated on to Nutrient agar, and grown overnight at 37ºC to enumerate survivors. 
This work was carried out at the Eastman Dental Institute. 
 
4.5. Results 
4.5.1. Characterisation 
Analysis of iron oxide nanoparticles formed in the presence of carboxylic acid 
functionalised ligands via a coprecipitation method was carried out using X-Ray 
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diffraction (XRD) on a Bruker DX8 using CuKα radiation, 1.54 Å; Raman using a 
Renishaw inVia Raman Microscope with a laser wavelength of 785 nm and power 
of 1%; Infrared (IR) spectroscopy using a Perkin Elmer FT-IR Spectrometer 
Spectrum RX1; Thermogravimmetric analysis (TGA) using a Netzsh STA 449C 
instrument with Helium gas; Magnetometry on a quantum design magnetic property 
measurement system (MPMS)-5T and photon correlation spectroscopy (PCS) on a 
Zetasizer 3000 (Malvern, UK) was used to measure the hydrodynamic diameter of 
the nanoparticles in a plastic cuvette in distilled water at 25°C. 
 
XRD was run for all samples and, in all cases, confirmed a core composition of iron 
oxide in both magnetite and maghemite forms (Figures 4-2, 4-10, 4-16 and 4-21). 
The crystallite sizes for the samples were estimated using the Scherrer equation and 
peak broadening was taken into account using a Gaussian fit. The comparison was 
made to a LaB6 standard. 
 
4.5.2. Tiopronin 
 
Figure 4-2 XRD pattern of iron oxide nanoparticles synthesised in the presence of tiopronin 
at 700C via a coprecipitation method. 
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The tiopronin coated sample was identified as having a magnetite and maghemite 
composition as identified in the XRD pattern (Figure 4-2).184, 185 This composition is 
also confirmed in the Raman spectra (Figure 4-3) where there are both magnetite 
and maghemite shifts.186-188 The XRD peaks are broad indicating the small 
nanoparticulate nature of the core. The crystallite size was estimated to be 9.4 nm, 
using measurements of the full width half maximum of the peak at 35.690. The 
hydrodynamic size of the particles when suspended in distilled water was 135.2 nm 
with a polydispersity index of 0.265. 
 
 
Figure 4-3 The Raman spectra of both free tiopronin and iron oxide synthesised in the 
presence of tiopronin via a coprecipitation method. Raman shifts are coloured blue for 
maghemite and coloured red for magnetite. 
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Figure 4-4 FTIR spectra of free tetramethylammonium hydroxide (TMAOH), free 
tiopronin and iron oxide formed in the presence of tiopronin using TMAOH as a reducing 
agent. 
 
Figure 4-4 shows the FTIR spectrum for the tiopronin coated nanoparticles, free 
tiopronin and free tetramethylammonium hydroxide. The spectrum confirms the 
presence of Fe-O stretches at both the octahedral and tetrahedral sites. These can 
be seen in the large peaks around 580 and 620 cm-1.  
 
The elemental analysis confirmed the presence of carbon (1.54%), hydrogen 
(0.34%) and nitrogen (0.2%). TGA was run in an inert atmosphere to try to 
correlate these values and there is tentative evidence to suggest that these values 
correlated to the first mass loss between 0-1800C (Figure 4-5). The TGA residual 
mass is 89% of the total, this is likely to be the remaining inorganic nanoparticle 
core. 
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Figure 4-5 TGA of iron oxide nanoparticles formed in the presence of tiopronin via a 
coprecipitation method. The mass changes and residual mass at 10000C is indicated on the 
graph. 
 
 
Figure 4-6 is the SQUID magnetometry data for the tiopronin coated iron oxide 
nanoparticles. The sample is superparamagnetic due to the zero coercivity seen at 
300 K, when compared to the coercivity when the measurements are run at 10 K. 
The zero field cooling (ZFC) and field cooling (FC) curves are also shown in Figure 
4-6. Ms is 49 emu g-1 at 300 K. 
 
Chapter 4                                       Iron Oxide with Carboxylic Acid Functionalised Ligands 
 
93 
 
 
Figure 4-6 SQUID data collected for iron oxide nanoparticles synthesised using a 
coprecipitation method in the presence of tiopronin. The two M-H diagrams are at 10 K 
and 300 K. The bottom graph is the zero field and field cooled (ZFC and FC) data 
collected.  
 
The SPIONTiopronin was at a suitable pH for biomedical applications so was 
subjected to heat testing in the MACH machine. This sample produced an 
outstanding heating curve (Figure 4-7). This was compared to the best commercially 
available particles for magnetic hyperthermia; Bayer Schering’s Resovist and 
Micromod’s Nanomag 100 at equivilant concentrations. Figure 4-8 shows these 
results by comparing both the specific absorption rate (SAR) and intrinsic loss 
power (ILP).  
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Figure 4-7 The temperature of a 50 mg/ml solution of an iron oxide nanoparticle solution 
synthesised in a coprecipitation method with tiopronin. Due to water boiling the maximum 
temperature reached is 1000C. 
 
Figure 4-8 A comparison of both the specific absorption rate (SAR) and the intrinsic loss 
power (ILP) of iron oxide nanoparticles synthesised in a coprecipitation method in the 
presence of tiopronin, against commercially available iron oxide nanoparticles named 
Resovist and Nanomag 100. 
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Figure 4-9 is an illustration of the magnetic strength of the SPIONTiopronin ferrofluid, 
it is suspended in a 50 ml centrifuge tube from a rare earth magnet. 
 
Figure 4-9 Iron oxide nanoparticle ferrofluid synthesised in the presence of Tiopronin via a 
coprecipitation synthesis at 700C, suspended in 1 50 ml centrifuge tube from a NdFeB rare 
earth magnet. 
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4.5.3. Succinic Acid 
 
Figure 4-10 XRD pattern of iron oxide nanoparticles synthesised in the presence of succinic 
acid at 700C via a coprecipitation method. 
 
The succinic acid coated sample was identified as having a magnetite and maghemite 
composition as identified in the XRD pattern (Figure 4-10).184, 185 This composition 
was also confirmed in the Raman spectra where there are vibrations assignable to 
both magnetite and maghemite (Figure 4-11).187, 188 The XRD peaks are broad 
indicating the small nanoparticulate nature of the core. The powder was coarse 
making the XRD difficult to focus. The crystallite size was estimated using the 
Scherrer equation, as per the tiopronin coated sample. The average crystallite size 
was calculated to be approximately 7 nm. The full width half maximum was 
measured using peak 35.750. The hydrodynamic size of the particles when 
suspended in distilled water was 317 nm with a polydispersity index of 0.33. 
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Figure 4-11 The Raman spectra of both free succinic acid and iron oxide synthesised in the 
presence of succinic acid via a coprecipitation method. Raman shifts are coloured blue for 
maghemite and coloured red for magnetite. 
 
 
 
 
Figure 4-12 FTIR spectra of free tetramethylammonium hydroxide (TMAOH), free 
succinic acid and iron oxide formed in the presence of succinic acid using TMAOH as a 
reducing agent. 
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Figure 4-12 shows the FTIR spectrum for the succinic acid coated nanoparticles, 
free succinic acid and free Tetramethylammonium hydroxide. The spectrum 
confirms the presence of Fe-O stretches at both the octahedral and tetrahedral sites. 
These can be seen in the large peaks around 580 and 620 cm-1.  
 
The elemental analysis identified carbon (0.66%), hydrogen (0.52%) and nitrogen 
(0.62%). TGA was run to try to correlate these values but there was no clear match 
(Figure 4-13). The final mass loss around 4500C is likely to be the phase transition 
from maghemite to hematite. This phase transition is irreversible. The data indicates 
that 90% of the mass is the inorganic component. 
 
 
Figure 4-13 TGA of iron oxide nanoparticles formed in the presence of succinic acid via a 
coprecipitation method. The mass changes and residual mass at 10000C is indicated on the 
graph. 
 
Figure 4-14 is the SQUID magnetometry data for the succinic acid coated iron 
oxide nanoparticles. The sample is superparamagnetic; this is known because below 
the blocking temperature there is coercivity, as seen in the 10 K data, and above the 
blocking temperature there is zero and the plot at 300 K looks paramagnetic. The 
zero field cooling (ZFC) and field cooling (FC) curves are shown in Figure 4-14. Ms 
for SPIONSuccinic at 300 K is 49 emu g-1. 
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Figure 4-14 SQUID data collected for iron oxide nanoparticles synthesised using a 
coprecipitation method in the presence of succinic acid. The two M-H diagrams are at 10 K 
and 300 K. The bottom graph is the zero field and field cooled (ZFC and FC) data 
collected.  
 
The SPIONSuccinic sample was at a suitable pH for biomedical applications so was 
subjected to heat testing in the MACH machine (Figure 4-15). The sample did not 
respond well to the field and was far less efficient than the tiopronin coated sample. 
Due to this, no further cell or bacterial tests were carried out on this sample. 
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Figure 4-15 The heating response from the iron oxide nanoparticles synthesised by a 
coprecipitation method with the presence of succinic acid (SPIONsuccinic) when placed in 
an inductive magnetic field (MACH). 
 
4.5.4. Oxamic Acid 
 
Figure 4-16 XRD pattern of iron oxide nanoparticles synthesised in the presence of oxamic 
acid at 700C via a coprecipitation method. 
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The XRD and Raman spectra of SPIONOxamic shows there are assignable vibrations 
to both magnetite and maghemite (Figures 4-16 and 4-17).184, 185, 187, 188 The 
crystallite size was estimated to be 7.9 nm based on the full width half maximum 
measurement of peak 35.750. The hydrodynamic size of the particles when 
suspended in distilled water was 870 nm with a polydispersity index of 0.40. 
 
 
Figure 4-17 The Raman spectra of both free oxamic acid and iron oxide synthesised in the 
presence of oxamic acid via a coprecipitation method. Raman shifts are coloured blue for 
maghemite and coloured red for magnetite. 
 
 
Figure 4-18 shows the FTIR spectrum for the SPIONOxamic, free oxamic acid and 
free Tetramethylammonium hydroxide. The spectrum confirms the presence of Fe-
O stretches at both the octahedral and tetrahedral sites; around 580 and 620 cm-1.  
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Figure 4-18 FTIR spectra of free tetramethylammonium hydroxide (TMAOH), free oxamic 
acid and iron oxide formed in the presence of oxamic acid using TMAOH as a reducing 
agent. 
 
 
Figure 4-19 TGA of iron oxide nanoparticles formed in the presence of oxamic acid via a 
coprecipitation method. The mass changes and residual mass at 10000C is indicated on the 
graph. 
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The elemental analysis identified carbon (0.38%), hydrogen (0.32%) and nitrogen 
(0.01%). TGA was run to try to correlate these values and there is tentative evidence 
to suggest that this correlates to the mass loss between 0-1750C (Figure 4-19). 95% 
of the mass remains, most probably being the iron oxide core. 
 
 
Figure 4-20 SQUID data collected for iron oxide nanoparticles synthesised using a 
coprecipitation method in the presence of oxamic acid. The two M-H diagrams are at 10 K 
and 300 K. The bottom graph is the zero field and field cooled (ZFC and FC) data 
collected.  
 
Figure 4-20 is the SQUID magnetometry data for the oxamic acid coated iron oxide 
nanoparticles. The sample is superparamagnetic; this is known because below the 
blocking temperature there is coercivity, as seen in the 10 K data, and above the 
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blocking temperature there is zero and the plot at 300 K looks paramagnetic. The 
zero field cooling (ZFC) and field cooling (FC) curves are shown in Figure 4-20. Ms 
is 45 emu g-1 at 300 K. 
 
The SPIONOxamic was not at a suitable pH for biomedical applications so no heating 
data was collected. 
 
4.5.5. EDTA 
 
Figure 4-21 XRD pattern of iron oxide nanoparticles synthesised in the presence of EDTA 
at 700C via a coprecipitation method. 
 
As before, using the Scherrer equation the crystallite size was estimated to be 16.4 
nm for the SPIONEDTA sample. This was measured using the full width half 
maximum measurements of the peak at 35.750 on the XRD pattern (Figure 4-21). 
The XRD showed the sample was a mix of magnetite and maghemite.184, 185 The 
Raman peaks (Figure 4-22), again show that the nanoparticle is comprised of both 
magnetite and maghemite.187, 188 The hydrodynamic size measurements for 
SPIONEDTA dissolved in distilled water at room temperature was 378 nm with a 
PDI of 0.18. 
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Figure 4-22 The Raman spectra of both free EDTA and iron oxide synthesised in the 
presence of EDTA via a coprecipitation method. Raman shifts are coloured blue for 
maghemite and coloured red for magnetite. 
 
 
 
 
Figure 4-23 FTIR spectra of free tetramethylammonium hydroxide (TMAOH), free EDTA 
and iron oxide formed in the presence of EDTA using TMAOH as a reducing agent. 
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Figure 4-23 shows the FTIR spectrum for the EDTA coated nanoparticles, free 
EDTA and free Tetramethylammonium hydroxide. The spectrum confirms the 
presence of Fe-O stretches at both the octahedral and tetrahedral sites.  
 
Elemental analysis of the SPIONEDTA sample showed gave carbon (1.17%), 
hydrogen (0.4%) and nitrogen (0.14%). Figure 4-24 shows the TGA for the sample, 
the mass loss between 0-1900C is similar to the results of the elemental analysis. 
96% of the mass remained. 
 
 
Figure 4-24 TGA of iron oxide nanoparticles formed in the presence of EDTA via a 
coprecipitation method. The mass changes and residual mass at 10000C is indicated on the 
graph. 
 
Figure 4-25 is the SQUID magnetometry analysis of the SPIONEDTA sample. The 
sample is superparamagnetic; this can be seen by the small coercivity at 10 K and 
the zero coercivity at 300 K above the blocking temperature. The zero field cooling 
(ZFC) and field cooling (FC) curves are also shown in Figure 4-25. Ms is 61.8 emu g-
1 at 300 K. 
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Figure 4-25 SQUID data collected for iron oxide nanoparticles synthesised using a 
coprecipitation method in the presence of EDTA. The two M-H diagrams are at 10 K and 
300 K. The bottom graph is the zero field and field cooled (ZFC and FC) data collected.  
 
 
The SPIONEDTA was tested for heating efficiency in the MACH. It was largely 
unresponsive with a SAR value of 25.8 W/g and an ILP of 5.5 x 10-13 Hm2/kg, cf. 
SPIONTiopronin which was several orders of magnitude greater. Thus, no further 
testing for antimicrobial properties was pursued. 
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4.5.6. The Antibacterial Activity of the Tiopronin 
Coated Sample  
Due to the high ILP and SAR values from the SPIONTiopronin sample further 
investigation into the heating ability in an antibacterial capacity using a heat bath 
system was investigated in collaboration with the Eastman Dental Institute, London, 
UK. The bacterium chosen was Staphylococcus aureus NCTC 6571 and the heating 
response from SPIONTiopronin was induced using an inhouse patented system named 
MACH (see Chapter 2).  
 
Initially the toxicity of the SPIONTiopronin was tested, in all control cases there were 
no bacterial deaths, confirming that the SPIONTiopronin is non toxic under normal 
conditions; when no magnetic field is present. The initial experiment used a 
SPIONTiopronin concentration of 50 mg/ml. The solution was exposed to the MACH 
and a total kill of 107 cfu/ml was recorded with a boiling reached within 30s. 
Following this positive result the antibacterial properties of the sample was 
investigated over time, varying concentrations and length and type of magnetic field 
exposure. 
 
Six days after SPIONTiopronin preparation a 50 mg/ml concentration was studied 
under varying the length of time and type of exposure to the MACH. The variations 
were a continuous 2 minutes, continuous 1 minute, 3 exposures of 20 seconds and 6 
exposures of 10 seconds. The results that show that with decreasing exposure time 
and decreasing continuous exposure the kills recorded are less can be seen in Figure 
4-26. 
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Figure 4-26 The bacterial count of S.aureus after exposure to iron oxide nanoparticles 
synthesised in a coprecipitation method in the presence of tiopronin, and at a 
concentration of 50 mg/ml in an inducing magnetic field. The field exposure time was 
varied to be continuous for 120s or 60s or to be pulsed for 3 x 20s and 6 x 10s. The 
experiment was run 6 days after SPION preparation. 
 
Figure 4-27 shows the antibacterial study taken 7 days after SPIONTiopronin was 
prepared. Again, the 50 mg/ml conctration was recording total kills and the bath 
reached a maximum temperature of 1000C (boiling). This maximum temperature 
was also found in the 25 mg/ml but the rate at which it reached this was slower; 60C 
per minute. The maximum bath heating temperatures and bacterial kills reduced 
with decreasing SPIONTiopronin concentration.  
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Figure 4-27 The bacterial count of S.aureus after exposure to iron oxide nanoparticles 
synthesised in a coprecipitation method in the presence of tiopronin (T) in an inducing 
magnetic field (MACH). The concentration of the nanoparticles was varied to be 50, 25, 
12.5 and 6.25 mg/ml. In the case of the 50 mg/ml result, no blue bar shows that when 
exposed to the MACH there was a total kill of bacteria. The temperature that the water 
bath reached in each case due to the heat effect from the hyperthermic response of the 
particles is indicated above. The experiment was run 7 days after the particles had been 
prepared. 
 
Figure 4-28 shows the results 19 days after SPIONTiopronin preparation. Both 25 
mg/ml and 50 mg/ml concentrations were used in this investigation to see how 
sample aging affects the bacterial kill count. The S.aureus was as neat, diluted 1:10 
with PBS and diluted 1:100 in PBS. The 50 mg/ml sample consistently gave a 3 
log10 kill at all dilutions. 
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Figure 4-28 The bacterial count of S.aureus after exposure to iron oxide nanoparticles 
synthesised in a coprecipitation method in the presence of tiopronin, and at concentrations 
of 50 mg/ml (dark blue) and 25 mg/ml (light blue) in an inducing magnetic field. The 
S.aureus was wither not diluted, diluted to 1 part in 10 of PBS or 1 part in 100 of PBS. The 
experiment was run 19 days after the nanoparticle preparation. 
 
4.6. Discussion 
4.6.1. Sample Analysis 
The data collected for all four samples showed similar results. FT-IR presented 
evidence for ligand coordination with νC-N and νO-H prevalent on all spectra. νFe-
O stretches were strongly evident. In all cases the elemental analysis showed that 
very low concentrations of the organic ligand were attached to the iron oxide 
surface. Cases where TGA analysis was obtained did not correspond to any 
significant mass losses, however in the case of SPIONTiopronin, SPIONSuccinic and 
SPIONEDTA the first mass losses showed tentatively to corroborate with the 
elemental analysis of the coated nanoparticles. This information indicates that the 
carboxylic acids were present but were in small amounts coordinated to the 
nanoparticle.  It is important to note that the pH values for all the samples varied 
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when the powder was resuspended in deionised water, particularly, that of the 
samples SPIONEDTA and SPIONOxamic which at a pH of 5.38 and 3.95 were 
significantly lower than the other two samples and strongly indicate the presence of 
the acid. If there was any excess of the base TMAOH a high pH would have been 
seen. Without the presence of the carboxylic acids, it was not possible to collect 
isolated nanoparticles as following the dialysis purification the particles were noted 
to have precipitated out of solution. The pH changes can be explained by the 
presence of free unattached molecules of tiopronin, oxamic acid, succinic acid, and 
EDTA, however the intense purification process would have vastly eliminated this. 
The IR and Raman show that the total mass of the relatively heavy nanoparticle 
makes the stretches on the ligands difficult to observe, further indicating only a low 
presence of ligand attached to the iron oxide nanoparticles. 
 
Hydrodynamic size measurements gave an average particle diameter of 135.2 nm for 
SPIONTiopronin with a polydispersity index of 0.265. The hydrodynamic size 
measurements for SPIONSuccinic, SPIONOxamic and SPIONEDTA gave larger results, 
317, 870 and 378 nm respectively, with the measurement for SPIONOxamic being 
very polydisperse, 0.40, compared with 0.18 for SPIONEDTA and 0.33 for 
SPIONSuccinic.  These hydrodynamic measurements are significantly larger than the 
crystallite sizes observed by XRD line-broadening, however this is because they are 
taken of full particle measurements in an aqueous environment. 
  
M-H curves produced using the MPMS at 300 K and 10 K show that all four  
samples have little/no remnant magnetisation at 300 K, indicative of 
superparamagnetism. The zero field cooling (ZFC) curves all demonstrated a broad 
peak. A possible, although by no means conclusive explanation for this, could be 
that this is the Verwey Transition temperature. The deviation from the literature 
value may indicate that there has been some oxidation of the Fe(II) to Fe(III), 
which is likely to have occurred at the surface and not throughout the bulk. If this is 
the case, it would also imply that the particle size is small, thus having a large surface 
area.189 190 
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4.6.2. Antibacterial Evaluation 
SPIONTiopronin, SPIONOxamic and SPIONEDTA all responded to an AC magnetic field 
producing an increase in temperature of the surroundings, SPIONOxamic was not 
tested as was too acidic to be further considered for any biomedical application. The 
strongest and most efficient was SPIONTiopronin which was then compared to two 
samples that are commercially available (Bayer Schering’s Resovist and Micromod’s 
Nanomag 100 nm), these two were identified as being useful for comparison after a 
study that was completed by Kallumadil in this group.133 It was found to be over 4 
times a better heater when placed inside the MACH system, when comparing the 
specific absorption rate and the intrinsic loss power. The measurements taken of the 
commercially available samples are in agreement with the measurements previously 
taken by Kallumadil. It is probable that the tiopronin in solution with the iron 
precursors limits the growth time after nucleation, giving rise to smaller particles 
that have high stability, thus low aggregation at neutral pH. This size optomisation 
of the particles leads to the superparamagnetism desired and an efficient response to 
the AC magnetic field. 
 
This preliminary data meant SPIONTiopronin was suitable for further investigation as 
it was able to cause a significant heating effect that was potentially able to denature 
cells. The experiments showed that at concentrations of 25 mg/ml and 50 mg/ml it 
is possible to achieve killing of S. aureus by several orders of magnitude after a 2 
minutes exposure in the MACH system. There was a direct correlation between the 
concentration of the ferrofluid and the kills achieved. The rate of killing was very 
much dependent on the temperature achieved. The initial testing showed that at a 
concentration of 50 mg/ml a total bacterial kill was seen and the sample was readily 
heated to 1000C. A concentration of 50 mg/ml was still producing the same results 
more than one week after initial testing when the nanoparticles were stored at 40C. 
At the lowest concentration tested (6.25 mg/ml), the temperature reached was only 
45.5oC and consequently no significant bacterial kills were seen, a reasonable 
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explanation of this is that S. aureus is a mesophile and is known to tolerate short 
exposure (10 minutes) to a temperature of 50oC.  
 
After 19 days and sonication, the antibacterial effectiveness of the iron oxide 
nanoparticles was reduced but at 50 mg/ml they were still achieving more than a 3 
log kill. This suggests that aging does have an effect on the composition and time 
and sonication oxidise the iron oxide. Indeed, there was a colour change from black 
to brown of the particles that is indicative of this. For longevity it would be best to 
keep the particles in an inert atmosphere until they needed to be used, however it is 
important to note that they will not degrade instantly and this makes them useful for 
the commercial and biological purpose they are intended for.  
 
The exposure time to the MACH is also an important parameter which affects the 
bacterial kill, when using a 50 mg/ml concentration it was shown that total kill of a 
suspension containing 107 cfu/ml of bacteria was achieved after a two minute 
constant exposure. At one minute there was less kill, approximately 1.5 orders of 
magnitude being acheived. When bacteria were added to nanoparticles that had 
previously been exposed to a magnetic field in the MACH system, no killing was 
detectable. This finding suggests that the bactericidal effect observed in the other 
experiments is solely due to the heating effect of the particles rather than potential 
heat-induced release of toxic moieties from the nanoparticles.  Functionalisation of 
the nanoparticles with bacteria-targeting moieties would enable the achievement of a 
localised heating effect and consequent bacterial killing without an accompanying 
temperature rise in host tissues.  Following such a development, this novel means of 
killing bacteria could form the basis of a new approach to the treatment of 
infectious diseases.     
 
4.7. Conclusions 
The synthesis of iron oxide nanoparticles in the presence of four carboxylic acid 
functionalised ligands has been shown to change both the solubility properties, pH 
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in water and overall particle size. The particles which gave the best heating response 
to an alternating AC magnetic field were those which were formed with the ligand 
N-(2-Mercaptopropionyl)glycine (Tiopronin), SPIONTiopronin. This gave a stable 
solution of iron oxide nanoparticles suspended in water at a biomedically favourable 
pH. This nanoparticle solution was shown to have an outstanding response to an 
AC magnetic field at various concentrations. The heating ability of this solution was 
over 4 times better than that of the best commercial samples; Bayer Schering’s 
Resovist and Micromod’s Nanomag 100 nm.  
 
There was a direct correlation between the nanoparticle concentration and the kills 
of S. aureus. At 50 mg/ml a total kill of over 107 cfu of the bacteria was reported. 
Total kills were also achieved after a week using 50 mg/ml. Log magnitude bacterial 
kills were seen up to 19 days after initial testing, although there was evidence that 
the solution did degrade with time and sonication. The concentration of the 
SPIONTiopronin sample, and its AC field exposure time and type (pulse or 
continuous) varied heating efficiency and thus kill rates. We believe this to be the 
first time magnetic hyperthermia has been used to kill bacteria.  It is possible that 
this approach may offer, following the development of a specific targeting system, a 
novel approach for the treatment of a variety of infectious diseases, an example of 
which is septacemia. 
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Chapter 5  
Iron Oxide in the Presence of  
Phosphonate Functionalised 
Ligands 
 
5.1. Introduction 
As detailed in Chapter 4, phosphonates and bisphosphonates are a group of organic 
compounds that are being investigated in the stabilisation of iron oxide 
nanoparticles. Various phosphonates and bisphosphonates have previously 
successfully coated iron oxide nanoparticles whilst also promoting dissolution into 
aqueous media. A bisphosphonate has 2 phosphonate groups connected to a 
carbon, this is not to be confused with a diphosphonate that has 2 phosphonate 
groups but does not have a characteristic P-C-P backbone. The phosphonates have 
been used as coatings due to their strong chelating ability with metal ions, in 
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particular iron, and also for their proven biocompatibility. Examples include, but are 
not exclusive to, nitrilo tri(methanephosphonic) acid, diphosphoglyceric acid, 
etidronic acid, imino di(methanephosphonic) acid and 5-hydroxy-5,5-
bis(phosphono)pentanoic acid, with the bisphosphonates proving to be better than 
the phosphonates.154, 155  
 
The di- and bisphosphonates have been developed as pharmaceuticals due to their 
affinity for calcium which is abundant in bone. The bisphosphonate structure is 
analogous to the naturally occurring pyrophosphates which have a P-O-P backbone. 
These drugs are prescribed for illnesses including; osteoporosis, Paget’s disease and 
myeloma, because they stop bone resorption by interfering with osteoclasts,191 the 
cells which break down the bone matrix.35  
 
Due to their metal chelating abilities bisphosphonate magnetic nanoparticles have 
been used to remove toxins from water and blood; an example of such is the work 
by Wang et al. that was able to remove UO22+ ions from blood.192 
 
Shafi et al. investigated the interaction between various ligands and maghemite 
nanoparticles.193 In comparison to the carboxylates and sulphonates they found that 
the extra negative charge in the phosphonate group causes it to be a strong bridging 
bidentate ligand, which has a stronger ionic bond with the Fe (III) of the 
nanoparticle. They put forward a theory that this also reduces the number of 
unpaired spins on the nanoparticle via a double superexchange from Fe(III)-O-P-O-
Fe(III). Their results also showed that the presence of this bridging ligand resulted 
in a reduction in the magnetisation and they suggested that these surface ions are 
antiferromagnetically coupled with the phosphonate and this leads to 
superantiferromagnetic particles, as the phosphonate did not alter the particle size. 
Yee et al. also described low saturation magnetisation values when surface 
functionalising maghemite with octadecanephosphonic acid.194 They too believe this 
to be due to interactions between the empty d orbitals on phosphorus and the 
Fe(III) spins on the surface. 
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In stark contrast to this work, Ngo et al. suggested that polyphosphate maghemite 
particles had no decrease in magnetisation.195 Likewise, Daou et al. carried out 
similar experiments on 39 nm magnetite particles. They found that a carboxylate will 
cause spin canting in the oxidised surface of the nanoparticle resulting in a decrease 
in net magnetisation, whereas no such effect was observed when a covalently linked 
phosphonate was attached.196 Figure 5-1 is taken from this paper and demonstrates 
these differences. 
 
 
Figure 5-1 Diagram taken from Daou et al. demonstrating the effect of a carboxyl or a 
phosphonate ligand to the magnetism of a magnetite nanoparticle. The arrows within the 
nanoparticle cross sections represent the direction of the magnetic moments.196 
 
5.2. Chapter Motivation 
The phosphonates have been chosen for further investigation in the stabilisation of 
iron oxide nanoparticles in magnetic hyperthermia. The reasoning behind this 
thread of exploration, is that it has been shown that the carboxyl binding on metal 
oxide nanoparticle surfaces are much weaker, causing them to be washed away, 
whereas the phosphonates are much more strongly bound, and are preferentially 
attached over a carboxyl group causing them to still be interesting to research in the 
stabilisation of iron oxides.197 
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Due to the strong anchoring that a phosphonate has to the magnetic nanoparticle 
surface, and by selecting ligands that have alternative organic functional groups on 
them, it has been shown that further attachment chemistry can be performed to fix 
other moieties to the particle. Such an example of this ability is the attachment of 
the enzyme β-glucosidase using 4-(aminomethyl)benzylphosphonic acid as a 
linker.198 This property is attractive for the application of magnetic hyperthermia for 
cancer therapy, as antibody fragment attachment is required to ensure heat targeting 
is specific to cancer cells. 
 
Excitingly, some bisphosphonates have been shown to have antitumor properties of 
their own. An example of such is Zoledronate which is targeting to breast and 
prostate tumour cell lines.199 By adhesion to a nanoparticle surface it is possible to 
ensure a dosage to these tumour cells as opposed to the drug being accumulated to 
its preferential tissue; the bone. 
 
The methodologies reported for the complexation of phosphonate ligands include 
long periods of sonocation,154 dialysis at low temperatures and using exchange 
resins.155 This chapter looks at a new approach to see if the synthesis is possible 
using a one pot method that was reported in Chapter 4. 
 
Finally, it cannot be ignored, as mentioned in section 5.1, that there is disagreement 
within the community regarding the effect a phosphonate has on the magnetic 
properties of a magnetic nanoparticle. However, until there is firm accord the 
phosphonates should not be discounted, this chapter looks to shed further light on 
these magnetic capabilities, and if this will indeed mean that phosphonated 
nanoparticles can be used in magnetic hyperthermia. 
 
5.2.1. Ligand Selection 
The desired outcomes of this chapter meant that the ligands selected needed to 
satisfy certain criteria. These were: 
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• water solubility so that a one pot synthesis could be achieved without the 
need for a phase transfer agent 
• had two phosphonate groups 
• at least one ligand needed to have a P-C-P backbone 
• further attachment chemistry could be achieved by the presence of at least 
one other functional group 
• they had proven biocompatibility 
 
Due to availability, the two ligands selected were N,N-bis(phosphonomethyl) 
glycine (DPG) and 1-hydroxyethylidenediphosphonic acid (etidronic acid) (Figure 5-
2). Both of these ligands have been studied previously by Portet et al.155 where they 
investigated the attachment and stability of the phosphonate-iron oxide colloid 
through a different synthetic route, however, no further investigation into the 
magnetic properties, and most certainly their use in magnetic hyperthermia, has 
been performed to the best of the authors knowledge. 
 
 
Figure 5-2 The two phosphonate functionalised ligands selected for the coating of the iron 
oxide nanoparticles synthesised via a coprecipitation method. 
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Etidronic acid is prescribed extensively as a treatment for many bone diseases.200-202 
Examples include osteoporosis and Paget’s disease which are the first and second 
most common forms of bone disease respectively.203   
 
DPG is normally used in agriculture,204, 205 however, it is under investigation in a 
clinical capacity. DPG has been attached to platinum (II) antitumour drugs to 
increase targeting to bone metastasis that occur in breast cancer patients.206 
  
5.3. Synthesis 
5.3.1. Materials 
All chemicals were purchased from Sigma Aldrich and were used as received with 
no further purification; iron (III) chloride hexahydrate (99%), iron (II) chloride 
tetrahydrate (≥99%), tetramethylammonium hydroxide (25% in water w/w) 
(TMAOH), N,N-bis(phosphonomethyl)glycine (≥98%), 1-
hydroxyethylenediphosphonic acid monohydrate (etidronic acid) (≥95%). All water 
used was distilled.   
 
5.3.2. Methodology 
Similarly as to what was seen in the EDTA coating of iron oxide nanoparticles by 
coprecipitation (Section 4.3.3.), when the phosphonates were in the reaction vessel 
with the iron salts, an intractable mixture formed due to the strongly chelating 
properties of the ligands. Therefore an adapted methodology was pursued. 
 
10 mmol of FeCl3.6H2O in degassed water was placed into a round bottomed flask 
under constant nitrogen flow. To this was added 5 mmol of FeCl2.4H2O in degassed 
water solvent. Due to the magnetic nature of the desired product the reactants were 
stirred mechanically using an overhead stirrer. The flask was heated in a silicone oil 
bath to 700C. Once at temperature 21 ml of TMAOH (25% in water w/w) was 
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added dropwise to the vigorously stirred solution. A black precipitate formed. After 
addition of the TMAOH the flask was immediately removed from the heat source 
but stirring continued. Once at room temperature an aqueous solution containing 5 
mmol of the phosphonate ligand (DPG or etidronic acid) was added and the 
solution stirred overnight. This was then made up to 50 ml with distilled water and 
then transferred to a wet 20 cm strip of dialysis tubing (cellulose membrane, M.W. 
12,400, average flat width 79 mm). This was secured and fastened at both ends and 
a magnetic stirrer attached. The membrane was placed into a 5 L beaker with 
approximately 4.5 L of 15 MΩ distilled water and stirred by placing on a magnetic 
stirrer plate. The water was recharged daily for 7 days. Upon completion of dialysis, 
the membrane was removed and the product was placed in a -800C freezer 
overnight, frozen and put under a high vacuum to remove the solvent. This freeze 
drying process took between 2-3 days and left a dry, brown powder. 
 
Both the nanoparticle-DPG (SPIONDPG) and nanoparticle-etidronic acid 
(SPIONEtidronic) samples were readily resuspended in water without the need of any 
extra assistance such as heating or sonocation. The pH of the solutions made were 
6.24 for SPIONDPG and 5.79 for SPIONEtidronic when at a concentration of 50 
mg/ml in water and at room temperature. 
 
5.3.3. Characterisation 
Analysis of iron oxide nanoparticles formed in the presence of phosphonate 
functionalised ligands via a coprecipitation method was carried out using X-Ray 
diffraction (XRD) on a Bruker DX8 using CuKα radiation, 1.54 Ǻ ; Raman using a 
Renishaw inVia Raman Microscope with a laser wavelength of 785 nm and power 
of 1%; Infrared (IR) spectroscopy using a Perkin Elmer FT-IR Spectrometer 
Spectrum RX1; Thermogravimmetric analysis (TGA) using a Netzsh STA 449C 
instrument with helium gas; Magnetometry on a Quantum Design magnetic 
property measurement system MPMS-7 and photon correlation spectroscopy (PCS) 
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on a Zetasizer 3000 (Malvern, UK) was used to measure the hydrodynamic diameter 
of the nanoparticles in a plastic cuvette in distilled water at 25°C. 
 
5.4. Results 
XRD was run for all samples and, in all cases, tentatively confirmed a core 
composition of iron oxide in both magnetite and maghemite forms (Figures 5-3 and 
5-8). The crystallite sizes for the samples were estimated using the Scherrer equation 
and peak broadening was taken into account using a Gaussian fit. The comparison 
was made to a LaB6 standard. 
 
5.4.1. DPG 
 
Figure 5-3 XRD pattern of DPG coated iron oxide nanoparticles synthesised via a 
coprecipitation method at 700C. 
 
The SPIONDPG particles were made using a one pot, two step modified 
coprecipitation synthesis. The use of the Scherrer equation in analysing the XRD 
data (Figure 5-3) gave an average crystallite size of 6.6 nm. The composition is a 
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magnetite-maghemite mix.184, 185 The hydrodynamic diameter was measured to be 
962 nm with a polydispersity index of 0.40. 
 
 
Figure 5-4 Raman spectra of DPG coated iron oxide nanoparticles formed via a 
coprecipitation method. There are corresponding peaks on the sample to that of the DPG 
ligand. The area between 790-1010cm-1 is highlighted for better clarity. Raman shifts are 
coloured blue for maghemite, red for magnetite, and purple for DPG. 
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Raman spectroscopy was run (Figure 5-4) and confirmed that there was a broad 
peak around 620 cm-1 that is indicative of an iron oxide, magnetite/maghemite, 
core.186-188 The Raman spectra also confirm the presence of peaks arising from the 
DPG ligand in the SPIONDPG sample around 930-1000 cm-1.207 208 This has been 
highlighted and a close up taken (Figure 5-4). 
 
 
Figure 5-5 FTIR spectra of DPG coated iron oxide nanoparticles formed via a 
coprecipitation method. The spectrum of the free DPG and free tetramethylammonium 
hydroxide (TMAOH) that was used as a reducing agent are also shown. The area showing 
similar characteristics between the nanoparticle and the ligand which are not like that seen 
in the TMAOH are highlighted. 
 
FTIR spectroscopy (Figure 5-5) confirmed Fe-O stretches from Fe(III) in the 
octahedral and tetrahedral sites. These can be seen in the artefact under 650 cm-1. 
The peak at 580 cm-1 is less obvious in this sample due to the interference from the 
ligand stretches. There are some peaks that match both the ligand and TMAOH. 
However, there are some identifiable regions in the SPIONDPG sample that seem to 
mimic those seen in the free ligand, and are not seen in free TMAOH. This area, 
~1100-2000 cm-1, has been highlighted for clarity. In all 3 spectra there is a strong 
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OH characteristic around 3500 cm-1, which due to the abundance of OH, is 
unsurprising. 
 
Elemental analysis advised that carbon content was 12.53% of the mass, hydrogen; 
3.43% and nitrogen 3.67%. After the TGA was run, there was a residual mass of 
57% likely to be the nanoparticle core (Figure 5-6). 
 
Figure 5-6 TGA analysis of iron oxide nanoparticles coated in DPG using an adapted 
coprecipitation method. 
 
Figure 5-7 is the magnetic analysis of SPIONDPG. There is a small amount of 
coercivity, 60 Oe, at 10 K. At 300 K the curve has no coercivity; this indicates that 
the sample is superparamagnetic. Ms is 12 emu g-1. The ZFC and FC curves are also 
seen and the broad shoulder at 120 K being the broadened Verwey transition 
because of surface oxidation of magnetite to maghemite. 
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Figure 5-7 MH curves taken at 10 K and 300 K of etidronic acid coated iron oxide 
nanoparticles synthesised using an adapted coprecipitation method. The zero field cooling 
(ZFC) and field cooling (FC) curves are also shown. 
 
The material underwent testing in the MACH system (see Chapter 2) to measure its 
heating response to the magnetic field. The SAR value was 3.28 W/g and the ILP 
was 7.04 x 10-14 Hm2/kg. This material was the least efficient of those tested and 
synthesised (see Table 5-1). 
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5.4.2. Etidronic Acid 
 
Figure 5-8 XRD pattern of Etidronic acid coated iron oxide nanoparticles synthesised via a 
coprecipitation method at 700C. 
 
The XRD and Raman spectra of the SPIONEtidronic showed there were peaks that 
were indicative of an iron oxide nanoparticle.184, 185, 187, 188 The synthesis used was a 
coprecipitation technique with the addition of the etidronic acid ligand post 
nanoparticle formation within the same pot. The use of the Scherrer equation in 
analysing the XRD data (Figure 5-8) gave an average crystallite size of 17.3 nm. The 
hydrodynamic diameter was measured to be 177 nm with a polydispersity index of 
0.28. 
 
The strong etidronic acid peaks of PO3 were also prevalent in the Raman spectrum 
for the SPIONEtidronic (Figure 5-9).207 208 A close up around of 985-1015 cm-1 has 
been highlighted so that this peak is easier to identify in both spectra. 
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Figure 5-9 Raman spectra of etidronic acid coated iron oxide nanoparticles formed via a 
coprecipitation method. There are corresponding peaks on the sample to that of the DPG 
ligand. The area between 985-1015 cm-1 is highlighted for better clarity. Raman shifts are 
coloured blue for maghemite, red for magnetite, and purple for etidronic acid. 
 
Alongside the expected υFe-O stretch, seen in all the other samples at the sub 650 
cm-1 part of the FT-IR spectrum, there are two areas that seem to have strong 
characteristics of the etidronic acid ligand and cannot be attributed to an excess 
TMAOH (Figure 5-10). The artefacts are the broad gap between peaks at 1050-1450 
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cm-1 and the two small peaks that are seen between 600-900 cm-1. Again the υOH 
characteristic around 3500 cm-1 is very strong in all spectra. 
 
 
Figure 5-10 FTIR spectra of etidronic acid coated iron oxide nanoparticles formed via a 
coprecipitation method. The spectrum of the free etidronic acid and free 
tetramethylammonium hydroxide (TMAOH) that was used as a reducing agent is also 
shown. The area showing similar characteristics between the nanoparticle and the ligand 
which are not like that seen in the TMAOH are highlighted. 
 
Elemental analysis showed that the carbon content was 12.52% of the mass, 
hydrogen; 4.13% and nitrogen 2.65%. Following the TGA a residual mass of 61% 
remained; the inorganic component (Figure 5-11). 
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Figure 5-11 TGA analysis of iron oxide nanoparticles coated in etidronic acid using an 
adapted coprecipitation method. 
 
Figure 5-12 shows the sample to be superparamagnetic due to there being no 
coercivity at 300 K but approximately 20 Oe at 10 K. The Ms of SPIONEtidronic is 25 
emu g-1 at 300 K.  
 
Sample SAR / W/g ILP / Hm2/kg 
SPIONTiopronin 1179 6.1 x 10-9 
SPIONDPG 3 7.0 x 10-14 
SPIONEtidronic 7 1.5 x 10-13 
Resovist 279 1.5 x 10-9 
Nanomag 100 nm 263 1.4 x 10-9 
Table 5-1 Table showing the SAR and ILP values of SPIONDPG and SPIONEtidronic 
compared to SPIONTiopronin (Chapter 4) and commercially available samples Resovist and 
Nanomag 100 nm. 
 
The MACH testing of the material showed that of the two phosphonate 
functionalised SPIONs, SPIONEtidronic was the best with a SAR value of 7 W/g and 
an ILP of 1.5 x 10-13 Hm2/kg. However, these values were still significantly less that 
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those measured for carboxylic acid functionalised SPIONTiopronin and commercially 
available samples (Table 5-1) and so no further testing of the material for cell 
denaturing was carried out. 
 
 
Figure 5-12 MH curves taken at 10 K and 300 K of etidronic acid coated iron oxide 
nanoparticles synthesised using an adapted coprecipitation method. The zero field cooling 
(ZFC) and field cooling (FC) curves are also shown. 
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5.5. Discussion 
Both SPIONDPG and SPIONEtidronic were confirmed as being magnetite cores with 
oxidised maghemite surfaces, using XRD (Figures 5-3 and 5-8), FTIR (Figures 5-5 
and 5-10) and Raman (Figures 5-4 and 5-9) to confirm this.  
 
FTIR and Raman spectroscopy identified strong peaks from the phosphonate 
ligands in both of the phosphonated nanoparticles. TGA showed the residual 
masses for SPIONDPG and SPIONEtidronic to be 57% and 61% respectively. If the 
residual mass is taken to be the inorganic core component, this would indicate that 
roughly 40% of the mass is made up of the phosphonate organic shrubbery.  
Elemental analysis showed that significant amounts of the constituents of each 
ligand were detectable. This is strong evidence for the attachment of phosphonate 
to an iron oxide nanoparticle using a simple, two steps, one pot, methodology; 
coprecipitation followed by stirring with the ligand.  
 
An anomaly in the CHN analysis of SPIONEtidronic showed a reasonable amount of 
nitrogen still remaining (3.67%). This is even more than had been seen in the 
elemental analysis of the carboxylated SPIONS seen in Chapter 4, which may have 
come from traces of left over surfactant/reducing agent. Considering dialysis of the 
phosphonated SPIONS took place over a longer period of time, an extra 3 days, it 
would be expected that N content would at least be less than that seen in Chapter 4. 
A logical conclusion from this is that an in situ side reaction has occurred at the       
–OH terminus of the etidronic acid. Etidronic acid is a first generation 
bisphosphonate and is used as a starting material to synthesise N-containing 
bisphosphonates,98, 155, 209 7 and the evidence looks to indicate that that this has 
happened upon addition to the TMAOH rich solution in the synthetic process. A 
possible mechanism for this is detailed in Figure 5-13.  
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Figure 5-13 Schematic showing a possible mechanism for a nucleophilic addition to 
etidronic acid, following etidronic acid addition immediately after iron oxide nanoparticle 
formation in a coprecipitation synthesis using a base as the reducing agent. 
 
This shows that in base, deprotonation of the etidronic acid will occur. The 
electronegative oxygen atoms would draw the electron density towards them, 
creating a dipole with the positive dipole at the tertiary carbon. This tertiary carbon 
is then open to attack from a nucleophile and a nucleophilic addition can occur. In 
this example the base is the TMAOH and the nucleophile the nitrogen component 
of the TMAOH. Further investigation, particularly using NMR, without the 
magnetic particle, would be useful to determine this. Although not desired in this 
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process, this may be of importance in future development, whereby targeting 
antibody fragments could be anchored to the bisphosphonate in a simple step. 
Instead of using a nitrogen containing reducing agent, the iron salts could be 
reduced to iron oxide using sodium hydroxide and this could then preferentially 
attach a nitrogen containing an antibody fragment. 
 
The pH of the 50 mg/ml SPIONs in water was 6.24 and 5.79 for DPG and 
etidronic acid stabilised nanoparticles respectively. These indicate that the 
phosphonate ligands are present, as without these the pH of a stable iron oxide 
nanoparticle solution formed in a basic environment would have been in the basic 
range. The acidity of SPIONEtidronic is something that would need further 
investigation to see if this could be tolerated physiologically. However, this should 
not be discounted as the strong bond between the bisphosphonate and the particle 
surface make it an ideal candidate for the anchorage of further targeting moieties. 
With further functionalisation the etidronic acid coated nanoparticle could be better 
suited for magnetic hyperthermia by increasing its pH to near neutral, particularly if 
this is to be injected intravenously where the blood pH tolerance is very narrow, 
between 7.35 and 7.45.210 8 
 
The SQUID run at 10 K and 300 K does prove that SPIONDPG and SPIONEtidronic 
are superparamagnetic. This is because superparamagnetic materials behave 
differently above and below the blocking temperature; below the temperature 
coercivity is seen but above the material displays paramagnetic properties whereby 
there is nil coercivity. This was seen in the SQUID data taken of the nanoparticles. 
As described in Chapter 1, it is important for the biomedical applications that the 
SPIONs are superparamagnetic. The magnetic data indicates that the phosphonate 
attachment does not hinder this.   
 
The SQUID also indicates that the Ms values for both samples are less than that 
which is seen in the samples stabilised using a carboxylic acid functionalised ligand 
(Chapter 4). SPIONDPG was only approximately 12 emu g-1 and SPIONEtidronic was 
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25 emu g1. Also, unlike in the case of the carboxylated-nanoparticles where the 
saturation magnetisations values were equivalent, there is a marked difference 
between the two phosphonate ligands. This is unlikely to be because of the amount 
of magnetic material, as both TGA data sets gave residual masses of around 60%. 
This implies that there are equivalent masses of ligand present; this is because 
despite the etidronic acid being smaller and around 78% of the mass of DPG, due 
to sterics more of the ligand is able to associate to the nanoparticle. Alternatively, 
based on the hypothesis that the etidronic acid was modified by the TMAOH in the 
synthesis, the ligand may be larger and therefore carry a greater mass. Crystallite size 
estimations gave the SPIONDPG core as an average of 6 nm and SPIONEtidronic as an 
average of 17 nm. This could explain the difference in the saturation magnetisation. 
Further investigation, by addition of the ligands to the same initial nanoparticle 
solution could look to verify if the phosphonates affect the size, or if the 
nanoparticle size was already predetermined.  
 
If the difference in Ms is because of the ligand used, this indicates that SPIONEtidronic 
may be of more use in magnetic hyperthermia. It has been shown that SAR values 
are not necessarily bigger with larger Ms values,130 however, the SAR value for 
SPIONEtidronic is double that of SPIONDPG (6.8 and 3.28 W/g respectively) which 
mirrors that which is seen for the Ms values. In the case of SPIONTiopronin (Chapter 
4), the SAR value is 1179 W/g, when the Ms is 49 emu/g. The Ms of SPIONTiopronin 
is twice that of SPIONEtidronic and the SAR is over 173 times larger. This again 
shows that the SAR is larger when the Ms is larger, however, if these two values are 
intrinsically linked then the relationship is more complex than being directly 
proportional.  
 
5.6. Conclusions 
It has been shown that it is possible to stabilise iron oxide nanoparticles using a 
phosphonate functionalised ligand in a simple one pot process. This straightforward 
methodology shows that by immediately adding the ligand to a newly formed iron 
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oxide nanoparticle solution, and following stirring at room temperature, the ligand 
will attach. After purification from the excess surfactant/reducing agent used to 
synthesise the nanoparticles, the powder is readily soluble in water with no 
aggravation required. The type of ligand used does affect the pH of the ferrofluid, 
and therefore this should be a consideration when selecting phosphonate ligands for 
biomedical applications. Around 40% of the total mass of a powder came from the 
phosphonate indicating the abundance of ligand present, this is due to the strength 
of the nanoparticle-phosphonate interaction meaning washing and purification does 
not remove much of the ligand. 
 
The particles were superparamagnetic, which is highly desirable for the clinic. The 
saturation magnetisation, SAR and ILP values for SPIONEtidronic were twice that of 
SPIONDPG, this indicates that SPIONEtidronic may be more useful in magnetic 
hyperthermia, however these values were considerably lower than SPIONTiopronin at 
1179 W/g. 
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Chapter 6  
Conclusion 
6.1. Results Summary 
This thesis has investigated the synthesis and stabilisation of iron oxide 
nanoparticles prepared using a coprecipitation methodology, using either carboxylic 
acid or phosphonate functionalised ligands. This was for the purpose of improving 
biocompatibility and heating response when used in magnetic hyperthermia for 
biomedical applications.  
 
The coprecipitation method is a common synthetic route to nanoparticle formation 
by reducing the iron salts to iron oxide by pH adjustment. However, the chaotic 
reaction process occurring within the reaction vessel has meant that size, and thus 
property, control is difficult. The growth process that occurs in the literature is 
often cited to be Ostwald ripening, whereby due to the need to reduce surface 
energy, larger particles engulf smaller particles. With the desire to reach a better 
understanding of the growth process and to gain more control of size 
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determination, the effects of temperature and rate of addition of the reducing agent 
in the coprecipitation reaction to produce functionalised iron oxide nanoparticle was 
investigated. The results of these experiments showed that average particle and 
cluster size were co-dependent, and early evidence suggests they were proportional 
to temperature and inversely proportional to the addition rate of the reducing agent. 
The polydispersity of the nanoparticle was found to be linked in the same way.  
 
Using these results the growth mechanism in the formation of iron oxide 
nanoparticles was investigated. Interestingly, it has been shown that it cannot be 
assigned to just one type; Ostwald ripening. An alternative view is that depending 
on the reaction conditions different mechanisms would dominate. The theory put 
forward in this thesis is that increasing temperature means the coalescence 
mechanism is favoured, whereby growth occurs due to increased Brownian motion, 
and correctly orientated collisions between nanoparticles are more probable. 
Alternatively, with lower addition rate of the reducing agent, the traditional Ostwald 
ripening mechanism is preferred in this system. This is because there is more 
distance between nucleation points and more time between growth periods, causing 
the particles formed at the beginning to grow and internalise the newer, smaller 
particles. 
 
Alongside the formation of a magnetic core, stabilisation at neutral pH had to be 
achieved. Short chained carboxylic acid functionalised ligands and ligands with two 
phosphonate groups were chosen. The literature shows that phosphonates and long 
chain carboxylic acids are useful in stabilising SPIONs. The particles were 
synthesised in a one pot coprecipitation method where the ligand was either in situ 
(SPIONTiopronin, SPIONSuccinic, SPIONOxamic) or added post magnetite formation 
(SPIONEDTA, SPIONDPG, SPIONEtidronic). The weaker bond between the carboxylic 
acid and the nanoparticle was evident, because analysis showed only trace levels of 
the ligand in comparison to the phosphonate ligands, which were much easier to 
identify. The shelf life and ease of solubility were both better with phosphonated 
SPIONs. 
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Magnetic analysis of the ligand stabilised nanoparticles showed that the carboxylated 
SPIONs gave greater Ms values than their phosphonate analogues. Initially, it would 
seem that this may be because, per unit gram, there is less magnetic material in a 
phosphonate SPION. However, taking this into account, even SPIONEtidronic which 
had the largest Ms, has an average of only three quarters the Ms value of the 
carboxylated SPIONs. This gives further support to the groups that believe that the 
phosphonate groups interfere with the magnetism of the iron oxide nanoparticles. 
The thoughts being that the empty d orbitals on phosphorus interact with the 
Fe(III) spins and a possible double superexchange takes place.182 
 
Many of the samples reported in Chapters 4 and 5 were tested in the MACH for a 
positive heating response to an AC magnetic field. The only sample not to be tested 
was SPIONOxamic which was too acidic to be investigated further for biomedical 
applications. The SPIONs which were coated in a phosphonate functionalised 
ligand were less responsive to the field than the SPIONs coated in a carboxylic acid 
functionalised ligand. This mirrored that magnetic behaviour seen in the SQUID 
analysis.   
 
The SPIONTiopronin had the largest SAR/ILP reported to date. This was explored 
further and used in antimicrobial testing of Staphylococcus aureus using a water bath kill 
technique. The particles were non toxic when away from the inductive field of the 
MACH. Concentrations of 50 mg/ml gave consistent total kills and bath heating 
temperatures of 1000C. Total kill counts were proportional to particle concentration. 
It was also shown that a continuous exposure to the alternating field was more 
efficient than a pulsed field exposure in killing bacteria. This is an alternative 
application to cancer cell thermoblation, and it is hoped this may be of use in 
treating patients with bacterial infections, such as septicaemia, as the kill is 
indiscriminate and would therefore reduce the need for antibiotics. It is believed this 
is the first ever application of magnetic hyperthermia in antimicrobial studies.  
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6.2. Future Work 
As touched upon in Chapter 3, to understand the pathways to nanoparticle growth 
in a coprecipitation synthesis a new and thorough model is needed. This would give 
the experimentalist greater understanding and thus the ability to gain control of the 
synthesis for repeatable results. An experiment looking into each variable would 
need to be run followed by TEM imaging and DLS measurements. The variables 
not investigated in this thesis are; reactant concentrations, strength of reducing 
agent, surfactant contributions and mixing conditions. To each of these, trends in 
particle sizes could be indentified, and a hypothesis of the type of growth 
mechanism that dominates could be put forward. With this full set of data, an 
extensive and thorough model could be produced. The ability to control the 
nanoparticle coprecipitation synthesis is useful to all experimentalists using this 
technique, not just in the synthesis of magnetic nanoparticles. However, with size 
control comes the control on the magnetic properties, and this will be useful in fine 
tuning the “designer nanoparticle” for magnetic hyperthermia. 
 
The SPIONTiopronin has been shown to be an excellent heater. The thiol end group 
of the tiopronin would be useful in attachment chemistry and this could be 
attempted. The antimicrobial study could also be developed beyond a bath heating 
exercise to make it more useful in clinical applications. 
 
Further investigation on a suite of GMP approved bisphosphonates coated 
nanoparticles in the MACH would be useful to identify optimum heaters. It is the 
intention of this project that the particles can be used in the magnetic hyperthermia 
treatment of cancer cells. The attachment of targeting moieties to these stabilised 
nanoparticles is the next step in this work to be carried out at the Cancer Institute at 
UCL, London. It has been shown that this attachment could be made possible by a 
nucleophilic addition onto the tertiary carbon of etidronic acid all in the one pot 
process. This would certainly need further analysis, particularly using NMR, to 
establish where the nitrogen content of the sample has arisen from, but is an 
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interesting strand for consideration. The bisphosphonate functionalised ligands 
should also be studied in vivo, to see where they accumulate. It is proposed there 
might be preferential uptake in the bone, but this cannot be ascertained without full 
scrutinisation. If the affinity that the bisphosphonates have for the bone is still 
dominant upon nanoparticle attachment, they may also be used in targeting bone 
metastases which are common with breast cancer, thus being targeting without any 
further attachment chemistry. Finally, an antimicrobial examination, such as that 
seen with SPIONTiopronin, may also be interesting to develop. 
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